element_id,name
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:0,Glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1,central nervous system tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2,Plant alkaloids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:3,oncology treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:4,anti-GBM activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:5,Alkaloids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:6,glioma cell viability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:7,proliferation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:8,migration and invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:9,cell death
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:10,Bcl-2 and key signaling pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:11,antiangiogenic effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:12,tumor weight
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:13,survival rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:14,Noscapine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:15,favorable therapeutic potential
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:16,Lycorine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:17,Capsaicin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:18,Chelerythrine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:19,Caffeine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:20,Boldine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:21,Colchicine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:22,Tetrandrine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:23,greater risks than benefits
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:24,Nitidine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:25,Harmine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:26,Harmaline
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:27,Cyclopamine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:28,Cocaine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:29,Brucine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:30,Piperine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:31,toxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:32,Berberine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:33,poor bioavailability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:34,Kukoamine A
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:35,further pharmacological and toxicological evaluation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:36,Cyclovirobuxine D
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:37,α-Solanine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:38,Oxymatrine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:39,Rutaecarpine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:40,Evodiamine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:41,Photodynamic therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:42,light and a photosensitizer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:43,Nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:44,photodynamic therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:45,breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:46,Strategies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:47,therapeutic efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:48,reactive oxygen species production
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:49,photosensitizers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:50,photosensitizers in systemic circulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:51,Preclinical studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:52,improvements in therapeutic efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:53,Improvements in therapeutic efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:54,inhibition of tumor growth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:55,reduction in metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:56,improvement of immune microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:57,Doxorubicin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:58,anthracycline chemotherapeutic agent
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:59,various types of cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:60,hydralazine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:61,Combination of Doxorubicin and hydralazine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:62,cardioprotective combination therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:63,Combination therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:64,use of reduced Doxorubicin dose
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:65,Doxorubicin and hydralazine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:66,PEGylated liposomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:67,ethanol injection method
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:68,Lip-DOX-HDZ
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:69,158 ± 18 nm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:70,0.22 ± 0.08
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:71,-22 ± 5 mV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:72,Encapsulation efficiency of Doxorubicin in Lip-DOX-HDZ
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:73,90%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:74,Encapsulation efficiency of hydralazine in Lip-DOX-HDZ
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:75,30%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:76,MDA-MB-231 breast cancer cell line
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:77,MCF7 breast cancer cell line
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:78,HDF normal cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:79,H9C2 cardiac normal cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:80,normal cells compared to breast cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:81,Cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:82,iron
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:83,Iron
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:84,cancer cell proliferation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:85,cancer cell invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:86,cancer cell metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:87,Excess iron
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:88,reactive oxygen species
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:89,Reactive oxygen species
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:90,ferroptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:91,oncogenic signaling pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:92,Deregulation of iron metabolism in cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:93,anemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:94,toxic iron overload
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:95,gut microbiota
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:96,Lactoferrin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:97,strong iron chelating properties
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:98,iron to cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:99,cancer cell growth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:100,cancer progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:101,free Fe ions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:102,oxidative stress
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:103,mechanisms that promote carcinogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:104,immunomodulatory effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:105,anti-inflammatory effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:106,body's anti-tumor response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:107,Paclitaxel
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:108,multi-target antitumor effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:109,Camptothecin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:110,Curcumin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:111,Drug resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:112,applications of natural products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:113,Non-specific distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:114,Small RNAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:115,precise antitumor effects through gene regulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:116,low delivery efficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:117,degradation by nucleases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:118,Nanomaterial-based drug delivery systems
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:119,efficient platform for co-delivery of natural products and small RNAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:120,targeting of delivery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:121,synergistic antitumor effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:122,Androgen receptors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:123,up to 90% of human breast tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:124,estrogen-receptor signaling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:125,breast cancer biology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:126,new targets for therapeutic strategies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:127,Female canine mammary tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:128,a natural model for the study of human breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:129,similar histopathologies and molecular features to human breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:130,cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:131,Photothermal therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:132,standard therapeutic modalities for cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:133,Indocyanine green-loaded quenched nanoliposomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:134,activatable nanotheranostics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:135,Q-ICG-NLs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:136,significant quenching in near-infrared fluorescence emission
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:137,significant quenching in singlet oxygen generation upon light irradiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:138,Photothermal effect of Q-ICG-NLs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:139,photothermal effect of free indocyanine green
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:140,Fluorescence of Q-ICG-NLs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:141,cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:142,Singlet oxygen generation of Q-ICG-NLs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:143,selective detection of cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:144,phototherapy of cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:145,selective near-infrared fluorescence imaging of cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:146,image-guided photodynamic therapy of cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:147,image-guided photothermal therapy of cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:148,TGFBI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:149,PNI tissue
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:150,poor prognosis in pancreatic cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:151,Knockdown of TGFBI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:152,neural invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:153,EMT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:154,rTGFBI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:155,PI3K/AKT phosphorylation in Capan-2 and CFPAC-1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:156,PI3K inhibitor LY294002
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:157,TGFBI on neural invasion and EMT in Capan-2 and CFPAC-1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:158,tumor formation in the sciatic nerve of mice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:159,PI3K-AKT pathway in pancreatic cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:160,Activation of PI3K-AKT pathway by TGFBI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:161,PNI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:162,CDK4/6 inhibitor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:163,endocrine therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:164,CDK4/6 inhibitor added to endocrine therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:165,survival in HR+/HER2- metastatic breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:166,abemaciclib
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:167,gastrointestinal side effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:168,diarrhoea and abdominal pain
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:169,diarrhoea
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:170,symptom burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:171,quality of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:172,treatment adherence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:173,patients treated with abemaciclib and endocrine therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:174,strategies to control diarrhoea
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:175,dietary modifications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:176,non-prescribed medication use
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:177,nonadherence (dose interruption or reduction)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:178,Gliomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:179,24.5% of all primary brain tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:180,80% of all malignant tumors in adults
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:181,Vascular endothelial growth factor receptors tyrosine kinase inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:182,angiogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:183,tumor growth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:184,invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:185,VEGFR TKIs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:186,glioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:187,glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:188,Six-month progression-free survival rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:189,21%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:190,Twelve-month progression-free survival rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:191,15%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:192,Overall response rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:193,VEGFR TKIs in patients with glioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:194,limited efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:195,Epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:196,ultra-rare translocated vascular sarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:197,Pazopanib
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:198,first-line treatment in metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:199,35.1 months in metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:200,53.8 months in metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:201,12.6 months in patients with prior tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:202,105 months in patients with prior tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:203,6.1 months in patients with serosal effusion or systemic symptoms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:204,10.3 months in patients with serosal effusion or systemic symptoms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:205,Pazopanib treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:206,62% clinical benefit rate in metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:207,complete or partial responses in metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:208,pain and ascites reduction or hemoptysis in some patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:209,Pazopanib toxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:210,gastrointestinal
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:211,dose reductions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:212,One patient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:213,permanent treatment interruption due to toxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:214,patients with metastatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:215,sirolimus for specific patient subgroups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:216,centromere protein M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:217,non-small cell lung cancer tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:218,poor prognosis in non-small cell lung cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:219,overexpression of centromere protein M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:220,cell proliferation in non-small cell lung cancer cell lines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:221,tumorigenic potential of non-small cell lung cancer cell lines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:222,accelerated tumor progression in non-small cell lung cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:223,reduced survival time in tumor-bearing mice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:224,Wnt/beta-catenin signaling pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:225,cell division cycle 20/MYB proto-oncogene-like 2 axis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:226,inhibition of Wnt signaling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:227,tumorigenic potential induced by centromere protein M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:228,inhibition of cell division cycle 20/MYB proto-oncogene-like 2 axis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:229,non-small cell lung cancer development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:230,biomarker for predicting non-small cell lung cancer progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:231,Nonroutine discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:232,increased healthcare costs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:233,higher readmission rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:234,Sociodemographic factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:235,risk of nonroutine discharge in surgical patients with spinal metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:236,Disease-related factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:237,Other factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:238,Age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:239,sociodemographic factor influencing nonroutine discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:240,Race
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:241,Insurance status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:242,Marital status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:243,Family member involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:244,Spinal cord injury grade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:245,disease-related factor influencing nonroutine discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:246,Serum albumin level
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:247,Body mass index
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:248,Spinal surgery segment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:249,Type of surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:250,Preoperative functional dependency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:251,ASA grade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:252,Emergency versus elective surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:253,Activities of daily living at discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:254,Frailty index
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:255,other factor influencing nonroutine discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:256,Comorbidity index
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:257,Efficiency of the referral or discharge process
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:258,Early identification of patients at risk for nonroutine discharge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:259,implementation of a comprehensive nurse-led discharge plan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:260,Comprehensive nurse-led discharge plan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:261,hospital stay duration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:262,related complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:263,Succinate dehydrogenase
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:264,tricarboxylic acid cycle and electron transport chain
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:265,adenosine triphosphate production
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:266,cell physiology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:267,SDH deficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:268,many cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:269,Dysregulation of SDH
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:270,decreased catalytic activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:271,accumulation of succinate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:272,Accumulation of succinate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:273,tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:274,Defective SDH
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:275,carcinogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:276,SDH-deficient cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:277,gastrointestinal stromal tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:278,pheochromocytomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:279,paragangliomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:280,National Comprehensive Cancer Network Distress Thermometer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:281,distress in cancer genetics patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:282,patients aged 18 or older
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:283,low distress (DT score < 4) and high distress (DT score ≥ 4)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:284,younger age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:285,high distress
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:286,female sex assigned at birth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:287,personal history of cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:288,worry
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:289,commonly reported problem
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:290,fatigue
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:291,sleep disturbance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:292,patients experiencing high distress during cancer genetic counseling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:293,Craniopharyngioma surgery in children
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:294,high rate of recurrence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:295,morbid complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:296,Transcranial approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:297,most frequently proposed surgical technique
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:298,Transsphenoidal endoscopic approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:299,also used surgical technique
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:300,Surgical total removal
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:301,88% of cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:302,Children with hypothalamic involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:303,endocrine deficits
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:304,overweight or obese pre-operatively
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:305,early post-operative complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:306,late morbidities
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:307,Children with craniopharyngioma and strong hypothalamic involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:308,pre- and post-operative complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:309,Complete removal
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:310,high rate of cure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:311,global good neuropsychological results
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:312,Early multidisciplinary post-operative management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:313,long-term outcome
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:314,Surgery with total removal
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:315,definitive acceptable clinical results
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:316,Acute myeloid leukemia cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:317,aerobic glycolysis for energy metabolism
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:318,Activated T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:319,TP53-induced glycolysis and apoptosis regulator
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:320,glycolysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:321,AML cells from apoptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:322,TIGAR inhibition combined with 2-deoxy-D-glucose
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:323,therapeutic strategy for AML
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:324,TIGAR depletion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:325,CD8+ T cell counts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:326,CD4/CD8 ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:327,CD44 on CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:328,immune checkpoint CTLA-4 on CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:329,immune checkpoint LAG-3 on CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:330,immune checkpoint PD-1 on CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:331,"CD8+ T cells (IFN-γ, perforin, granzyme B, TNF-α)"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:332,"CD4+ T cells (IL-2, TNF-α)"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:333,cytotoxicity against AML cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:334,proliferation of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:335,apoptosis of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:336,TIGAR suppression with 2-DG
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:337,AML mouse survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:338,tumor burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:339,leukemic infiltration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:340,TIGAR suppression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:341,thymic T cell development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:342,peripheral immune balance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:343,High TIGAR expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:344,glycolysis pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:345,markers of T cell exhaustion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:346,Blocking TIGAR
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:347,CD8+ T cell dysfunction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:348,anti-AML immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:349,Lymphedema
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:350,oncological treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:351,Physical therapy interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:352,secondary lymphedema in patients with head and neck cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:353,Kinesio taping
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:354,lymphedema
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:355,Compression therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:356,Manual lymphatic drainage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:357,Exercise
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:358,Exercise program plus manual lymphatic drainage supplemented with kinesio taping or compression therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:359,external lymphedema
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:360,manual lymphatic drainage and exercise program
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:361,Neither therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:362,internal lymphedema
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:363,Adverse effects related to intervention
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:364,mild and transitory
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:365,tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:366,lipid peroxidation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:367,redox imbalance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:368,lipid overabundance within the tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:369,regulated cell death
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:370,lipid peroxidation products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:371,4-hydroxynonenal (HNE)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:372,lipid peroxidation and its products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:373,DNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:374,an environment conducive to tumor growth and metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:375,lipid peroxidation process
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:376,macrophages towards a pro-inflammatory phenotype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:377,antigen-presenting capacity of dendritic cells (DCs)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:378,cytotoxic functions of T and NK cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:379,neutrophils into pro-tumorigenic polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:380,lipid peroxidation of stroma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:381,advanced nanotherapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:382,tumor cells precisely
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:383,lipid peroxidation products and ferroptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:384,immunosuppressive state
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:385,ferroptosis-derived immunosuppression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:386,all types of immune cells within the tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:387,Liver metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:388,poor prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:389,Stereotactic body radiation therapy (SBRT)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:390,liver metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:391,durable tumor control
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:392,minimal toxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:393,Prescribed dose (PD)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:394,local control
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:395,Optimal threshold of 77.44 Gy EQD2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:396,1-year freedom from local progression (FFLP) rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:397,Internal breath-hold (iBH) with image-guided radiotherapy (IGRT)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:398,superior local control outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:399,high tumor control probability (TCP)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:400,other dose metrics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:401,3.9% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:402,grade ≥ 3 adverse events
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:403,highly effective and safe approach for liver metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:404,Prescribed dose (PD) and advanced imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:405,pivotal determinants of tumor control
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:406,Precise dosimetric planning and motion management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:407,SBRT outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:408,This study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:409,framework for personalized treatment strategies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:410,cornerstone in multidisciplinary management of liver metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:411,Conventional therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:412,oral squamous cell carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:413,Drug delivery systems based on nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:414,drug stability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:415,target accuracy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:416,Delivery of cisplatin via liposomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:417,40% improvement in tumor suppression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:418,PLGA nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:419,2.3 times more intertumoral drug accumulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:420,Nanoparticle platforms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:421,curcumin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:422,paclitaxel
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:423,therapeutic results
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:424,adverse effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:425,scaling issues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:426,Liposomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:427,circulation quickly
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:428,EGFR-targeted gold nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:429,selectivity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:430,effectiveness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:431,up to 90% receptor binding
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:432,tumors via EPR effect
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:433,immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:434,radiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:435,death of cancer cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:436,DNA damage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:437,cell division
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:438,Metallic nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:439,liver
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:440,Multifunctional platforms and stimuli-responsive nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:441,overcoming obstacles in OSCC therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:442,Clinical evaluation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:443,brain tumor progression monitoring
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:444,MR imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:445,Treatment effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:446,Pseudoprogression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:447,treatment effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:448,Radionecrosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:449,tumor heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:450,genetic divergence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:451,treatment resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:452,Surgical histopathological biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:453,additional valuable information
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:454,true
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:455,longitudinal measurements
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:456,Liquid biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:457,primary brain tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:458,brain metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:459,potential candidate for monitoring methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:460,Various analytes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:461,whole blood and its derivatives
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:462,cerebrospinal fluid
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:463,circulating nucleic acids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:464,extracellular vesicles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:465,platelet RNAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:466,circulating tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:467,disease progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:468,treatment response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:469,Tissue-resident memory T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:470,foreign antigens in non-lymphoid tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:471,antitumor immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:472,enhanced survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:473,tumor growth inhibition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:474,various cancer types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:475,tumor progression under certain conditions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:476,Tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:477,adverse outcomes during antitumor immune responses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:478,different tumor contexts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:479,combating cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:480,tumor development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:481,Chronic Myeloid Leukemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:482,Interleukin-18
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:483,platelet count
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:484,white blood cell count
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:485,PDW
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:486,RBC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:487,MCHC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:488,RDW-CV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:489,MCH
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:490,HCT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:491,PCT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:492,MPV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:493,RDW-SD
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:494,age distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:495,exosomes of MDA-MB-231 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:496,serum-free media
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:497,size distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:498,dynamic light scattering
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:499,exosome morphology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:500,scanning electron microscopy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:501,flow cytometry analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:502,metastatic markers CD105 and CD133 in exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:503,metastatic markers CD105 and CD133
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:504,exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:505,Aco-490
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:506,MDA-MB-231 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:507,MCF-7 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:508,CD133-positive exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:509,AKT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:510,extracellular signal-regulated kinase
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:511,cyclin D1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:512,MORC2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:513,cholangiocarcinoma progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:514,CCA cell proliferation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:515,cell cycle progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:516,TNF-α signaling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:517,NFKB signaling pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:518,Downregulation of MORC2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:519,cell cycle arrest
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:520,CCL3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:521,Upregulation of CCL3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:522,neutrophil infiltration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:523,immunosuppressive tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:524,Targeting MORC2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:525,patients with advanced CCA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:526,Immune checkpoint inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:527,Tumors with low tumor mutational burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:528,immune checkpoint inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:529,Mutations in DAXX
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:530,poorer survival outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:531,Mutations in HLA-A
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:532,Mutations in H3C2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:533,Mutations in IGF1R
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:534,Mutations in CTNNB1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:535,Mutations in SMARCA4
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:536,Mutations in KMT2D
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:537,Mutations in TP53
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:538,VHL mutations in renal cell carcinoma patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:539,improved overall survival following immune checkpoint inhibitor treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:540,Large language models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:541,information resource in oncology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:542,clinical decision-support tool
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:543,clinical outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:544,Studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:545,large language models in oncology as health information resource in question-answer style examinations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:546,large language models in oncology for diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:547,large language models in oncology for management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:548,Fine-tuning and prompt-engineering of large language models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:549,utility evaluation from 2022 to 2024
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:550,accurate information resource
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:551,clinician workload
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:552,accessibility and readability of clinical information
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:553,poor reliability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:554,hallucinations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:555,clinician oversight
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:556,medical information resource
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:557,clinical decision support tool
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:558,Further research
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:559,large language models in external hold-out datasets
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:560,medical accuracy of large language models across diverse clinical scenarios
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:561,Clinician supervision
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:562,large language models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:563,long segment losses exceeding 10 cm in the sciatic nerve
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:564,reconstructive techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:565,optimizing sensory and motor function recovery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:566,pedicled vascularized common peroneal nerve graft
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:567,14-cm sciatic nerve defect
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:568,L4 nerve root
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:569,L5 nerve root
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:570,S1 nerve root
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:571,patient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:572,neurofibromatosis type I
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:573,R0 tumor resection of the proximal left sciatic nerve
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:574,malignant peripheral nerve sheath tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:575,ipsilateral pedicled vascularized common peroneal nerve graft
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:576,reconstruction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:577,greater sciatic foramen into the inner pelvis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:578,MRC grade 4/5 strength in hamstrings with 90° knee flexion at 26-month follow-up
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:579,steady gait pattern at 26-month follow-up
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:580,ankle-foot orthosis at 32-month follow-up
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:581,single-staged surgery to restore motor function for large sciatic nerve defects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:582,common peroneal nerve
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:583,sural nerves for sciatic nerve reconstruction when sural nerves are insufficient or injured
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:584,miR-186-5p
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:585,acute myeloid leukemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:586,PD-L1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:587,miR-186-5p upregulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:588,acute myeloid leukemia cell multiplication
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:589,acute myeloid leukemia cell migration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:590,acute myeloid leukemia cell invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:591,acute myeloid leukemia cell death
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:592,proliferation activity of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:593,proliferation activity of CD4+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:594,activation markers Perforin and Granzyme B of CD8+ and CD4+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:595,"secreted cytokines IFN-γ, IL-4, TNF-α of CD8+ and CD4+ T cells"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:596,apoptosis of CD8+ and CD4+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:597,immune escape
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:598,knockdown of miR-186-5p
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:599,acute myeloid leukemia progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:600,PD-L1 upregulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:601,antitumor impact of miR-186-5p overexpression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:602,Tissue resident memory T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:603,cancer immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:604,solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:605,Presence of tissue resident memory T cells in solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:606,improved prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:607,response to therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:608,lung cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:609,Malignant pleural effusions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:610,non-small cell lung cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:611,14% of CD8+ T cells in malignant pleural effusions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:612,tissue resident memory T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:613,6% of CD4+ T cells in malignant pleural effusions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:614,CD45RO+CCR7-CD62L- and expressing 1 or both of CD69 and CD103
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:615,ITGAE and CD49A
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:616,"SELL, CCR7, and IL7RA"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:617,"T central memory cells in expression of PD-1, TIGIT, and CD39"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:618,"T effector memory cells in expression of PD-1, TIGIT, and CD39"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:619,"IFN-γ, TNF-α, and CD107a after stimulation with αnti-CD3 antibodies in vitro"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:620,T effector cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:621,CD69 expression on tissue resident memory T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:622,production of effector cytokines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:623,CD103 expression on tissue resident memory T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:624,Artificial intelligence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:625,healthcare system functions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:626,patient experience
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:627,Multidisciplinary teams
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:628,disease and management planning
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:629,holistic approach to patient care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:630,Holistic approach to patient care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:631,physical needs of patients and their families
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:632,psychological needs of patients and their families
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:633,social needs of patients and their families
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:634,colorectal multidisciplinary teams
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:635,quality of interdisciplinary discussions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:636,Enhanced quality of interdisciplinary discussions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:637,holistic patient-centered care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:638,numbers of late or misdiagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:639,Incorporation of artificial intelligence into multidisciplinary team meetings
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:640,reducing workload on healthcare professionals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:641,financial burden on pressurized healthcare systems
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:642,Tyrosine kinase inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:643,chronic myeloid leukemia outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:644,Survivors with chronic myeloid leukemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:645,semistructured interviews
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:646,self-reported questionnaires
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:647,Self-reported questionnaires
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:648,demographics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:649,perceived stress
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:650,side effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:651,emotional support
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:652,self-efficacy for managing chronic conditions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:653,Sixteen participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:654,the study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:655,Duration of TKI therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:656,0 to 12 years
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:657,31% of participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:658,treatment duration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:659,38% of participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:660,blood tests prior to treatment or TKI refilled
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:661,Qualitative data
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:662,five major themes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:663,Five major themes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:664,shock of diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:665,educational experiences regarding chronic myeloid leukemia and its treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:666,challenges in managing side effects and refills
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:667,importance of social support
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:668,strategies for maintaining remission and motivating adherence to tyrosine kinase inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:669,Patient-centered approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:670,health care providers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:671,adherence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:672,outcomes for chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:673,Hedyotis diffusa
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:674,quercetin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:675,BIRC5
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:676,Hedyotis diffusa against BRCA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:677,CDK1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:678,FOS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:679,HSP90AA1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:680,BIRC5 in MCF-7 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:681,CDK1 in MCF-7 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:682,HSP90AA1 in MCF-7 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:683,anti-BRCA effect of Hedyotis diffusa
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:684,sTPLS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:685,multiple pairs of datasets containing two types of features derived from different biological conditions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:686,11 gene-drug comodules specific for seven cancer types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:687,gene-drug comodules
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:688,seven cancer types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:689,two comodules shared across multi-type cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:690,multi-type cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:691,ovarian cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:692,colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:693,nine gene-peak comodules specific for five cell types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:694,three comodules shared across similar cell types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:695,similar cell types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:696,intermediate B cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:697,naïve B cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:698,shared and distinct cell communication patterns mediated by the MK signaling pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:699,cell communication patterns
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:700,coronavirus disease 2019 patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:701,healthy controls
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:702,Enhancer RNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:703,non-coding RNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:704,enhancer regions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:705,regulatory elements in gene expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:706,eRNAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:707,tumorigenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:708,metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:709,therapeutic response modulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:710,eRNA identification methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:711,enhancer region prediction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:712,histone H3 lysine 4 monomethyl chromatin signatures
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:713,nucleosome positioning analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:714,eRNA expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:715,RNA-seq
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:716,single-cell transcriptomics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:717,epigenomic integration approaches
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:718,gene expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:719,protein function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:720,chromatin modification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:721,databases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:722,eRNA annotations and interactions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:723,eRNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:724,immune cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:725,immune cell crosstalk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:726,tumor microenvironment reprogramming
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:727,eRNA signatures
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:728,predictive biomarkers for immunotherapy response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:729,predictive biomarkers for chemoresistance monitoring
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:730,multiple malignancies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:731,IgE deficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:732,higher risks of solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:733,higher risks of inborn errors of immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:734,higher risks of autoimmune disorders
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:735,hematological malignancies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:736,Selective IgM deficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:737,Asthma prevalence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:738,children with very high IgE
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:739,children with normal IgE levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:740,children with IgE deficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:741,Allergic rhinitis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:742,IgE-deficient children
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:743,Melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:744,Skin cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:745,majority of skin cancer-related deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:746,Early detection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:747,survival rates in skin cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:748,Multi-scale attention-based performance booster
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:749,Vision Transformer architecture
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:750,Vision Transformer models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:751,Convolutional neural network models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:752,Attention maps
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:753,discriminative regions within skin lesion images
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:754,Ensemble learning techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:755,several deep learning models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:756,Skin cancer classifier
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:757,Vision Transformer and EfficientNet models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:758,95.05% on ISIC2018 dataset
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:759,individual models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:760,Integrating attention-based multi-scale learning and ensemble methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:761,skin cancer classification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:762,Near-infrared Scan (NIRscan) probe
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:763,tumor localization accuracy and efficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:764,Convolutional neural network (CNN) model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:765,data from 133 breast phantoms into 266 samples
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:766,Data augmentation techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:767,mirroring
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:768,CNN model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:769,image reconstruction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:770,RMSE of 0.0624
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:771,MAE of 0.0360
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:772,R2 of 0.9704
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:773,Fuzzy Jaccard Index of 0.9121
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:774,Multitask CNN
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:775,images
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:776,"images based on depth, length, and health status"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:777,diagnostic capabilities
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:778,classification accuracy of 100% in depth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:779,classification accuracy of 92.86% in length
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:780,perfect F1 Score in health status classification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:781,NIRscan technology in combination with multitask CNN model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:782,real-time breast cancer screening and diagnostic workflows
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:783,Oncolytic herpes simplex virus
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:784,cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:785,host antitumor immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:786,T-VEC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:787,oncolytic herpes simplex virus drug
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:788,Delytact
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:789,Oncolytic herpes simplex virus products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:790,viral species and genetic modifications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:791,Viral species and genetic modifications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:792,therapeutic potential of oncolytic herpes simplex virus products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:793,Integration of oncolytic herpes simplex viruses with immunotherapeutic agents and conventional therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:794,promising future in treatment of malignant tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:795,Oncolytic virus therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:796,clinical relevance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:797,safety
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:798,efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:799,Human papillomavirus
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:800,benign lesions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:801,warts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:802,cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:803,Harald zur Hausen
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:804,Human papillomavirus to cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:805,2008 Nobel Prize
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:806,Head and neck cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:807,low five-year survival rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:808,Alcoholism
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:809,head and neck cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:810,Smoking
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:811,Human Papillomavirus infection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:812,oropharyngeal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:813,Patients with HPV-positive head and neck cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:814,better clinical prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:815,resistance to chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:816,HPV carcinogenic activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:817,"viral oncoproteins E5, E6, and E7"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:818,E5 oncoprotein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:819,immune evasion mechanisms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:820,tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:821,resistance to chemotherapeutic treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:822,Non-Hodgkin lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:823,HIV-1-positive individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:824,p17 variants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:825,lymphoma development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:826,"vp17s with amino acid insertions at positions 114-115, 117-118, and 125-126"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:827,HIV-positive individuals with lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:828,Alterations in primary amino acid sequences of vp17s
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:829,the protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:830,Destabilized vp17 protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:831,functional epitope
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:832,Functional epitope
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:833,protease-activated receptor-1 (PAR-1)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:834,protein kinase B pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:835,Stimulation of protein kinase B pathway by vp17s
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:836,oncogenic potential
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:837,Oncogenic potential of vp17s
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:838,lymphomagenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:839,Next-generation sequencing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:840,identifying HIV-positive patients at higher risk of lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:841,HPV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:842,nearly 5% of all cancers worldwide
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:843,cervical cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:844,oropharyngeal cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:845,HPV-positive head and neck squamous cell carcinomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:846,significantly improved treatment response compared to HPV-negative head and neck squamous cell carcinomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:847,Single-cell RNA sequencing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:848,immune cell populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:849,epithelial cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:850,Epithelial subpopulations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:851,transcriptome signatures
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:852,ontologies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:853,candidate biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:854,Distinct epithelial cell populations and reprogramming in HPV-negative versus HPV-positive HNSCC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:855,important components of the pro-tumor environment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:856,High-risk Human Papillomavirus infection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:857,cervical carcinogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:858,Single-nucleotide variants in CTLA4 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:859,gene expression and immune response against HPV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:860,cervical malignancy progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:861,T allele of -318 C>T
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:862,HPV infection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:863,high-grade squamous intraepithelial lesions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:864,TAG haplotype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:865,Early nutritional intervention
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:866,nutritional status in LANSCLC patients undergoing CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:867,incidence of weight loss ≥5% during CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:868,patient-generated subjective global assessments scores at the end of CCRT and 6 months after CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:869,incidence of grade 2+ radiation pneumonitis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:870,body mass index at the end of CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:871,prealbumin levels at the end of CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:872,progression-free survival in LANSCLC patients undergoing CCRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:873,Patients who responded well to oral nutritional supplements
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:874,Firmicutes/Bacteroidetes ratio at baseline
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:875,Gut microbiota
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:876,response to oral nutritional supplements
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:877,Cancer and related treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:878,body composition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:879,Impaired body composition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:880,malnutrition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:881,sarcopenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:882,Health-Related Quality of Life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:883,Predictive model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:884,unsupervised approaches including Principal Component Analysis and k-means clustering
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:885,Sarcopenia and malnutrition risks
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:886,"NRS-2002 and SARC-F questionnaires, anthropometric measurements, and Bioelectrical Impedance Analysis"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:887,EORTC QLQ-C30 questionnaire
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:888,Principal Component Analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:889,three main components
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:890,k-means clustering
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:891,three clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:892,Three clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:893,"High Muscle Profile, Moderate Muscle Profile, Low Muscle Profile"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:894,Patients in Low Muscle Profile
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:895,
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:896,comorbidities
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:897,increased risk of sarcopenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:898,Lung cancer site
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:899,Diabetes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:900,Malnutrition risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:901,Patients in Low Muscle Profile cluster
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:902,increased risk of sarcopenia (+62%)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:903,NUTRISCREEN project
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:904,personalized nutritional pathway for early screening of malnutrition and sarcopenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:905,Unsupervised approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:906,distinct body composition profiles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:907,insights into factors associated with sarcopenia risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:908,poultry consumption above 300 g/week
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:909,all causes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:910,gastrointestinal cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:911,men compared to women
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:912,Colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:913,cancer worldwide
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:914,cancer-related mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:915,Glucosinolates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:916,antitumoral capacity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:917,Polyphenols
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:918,ability to scavenge free radicals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:919,Free radicals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:920,cell damage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:921,Eruca sativa seed extract
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:922,highest antioxidant capacity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:923,Sinapis alba seed extract
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:924,Nutraceutical
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:925,Eruca sativa and Sinapis alba seed extracts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:926,73% after in vitro digestion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:927,thirty compounds responsible for antioxidant and tumoral prevention capacity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:928,Nutraceutical intake
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:929,31.6%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:930,53.9%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:931,Nutraceutical intake combined with physical exercise
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:932,52.3%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:933,62.6%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:934,Diet rich in bioactive compounds from Brassica species combined with physical activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:935,Vitamin D
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:936,immune system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:937,immune organ functions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:938,T-cell activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:939,tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:940,inflammatory responses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:941,vitamin D receptors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:942,immune responses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:943,adequate vitamin D levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:944,gene expression related to inflammation and cell proliferation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:945,"mechanisms that suppress cancer cell survival, proliferation, migration, and metastasis"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:946,low levels of vitamin D
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:947,increased risk of colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:948,vitamin D deficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:949,higher disease incidence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:950,"diet high in red meat and calories but low in fiber, fruits, and vegetables"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:951,colorectal cancer risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:952,physical inactivity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:953,insufficient calcium and vitamin D intake
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:954,disease occurrence and poorer clinical outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:955,maintaining optimal vitamin D levels and adequate dietary intake
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:956,patient prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:957,Unhealthy diet
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:958,Diet-related colorectal cancer burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:959,OECD countries
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:960,Diet-related colorectal cancer disability-adjusted life years
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:961,Global Burden of Disease 2021 study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:962,Diet-related colorectal cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:963,Age-standardised percentages of diet-related colorectal cancer DALYs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:964,OECD countries in 2021
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:965,Age-standardised percentages of diet-related colorectal cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:966,Age-standardised diet-related colorectal cancer DALYs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:967,1990 and 2021 in OECD countries
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:968,Age-standardised diet-related colorectal cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:969,Estimated annual percent change in diet-related colorectal cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:970,-1.26
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:971,Estimated annual percent change in diet-related colorectal cancer DALYs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:972,-1.20
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:973,Diet-related colorectal cancer DALYs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:974,4.1 million by 2050
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:975,0.2 million by 2050
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:976,Colorectal cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:977,1.33 from 1990 to 2050
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:978,Colorectal cancer DALYs in males
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:979,-0.90 from 1990 to 2050
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:980,Colorectal cancer DALYs in females
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:981,-1.0 from 1990 to 2050
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:982,Nutrition intervention programmes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:983,access to affordable and nutritious foods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:984,importance of healthy diet in reducing colorectal cancer risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:985,Moderate total iron consumption in the second quintile (5.00-6.27 mg/day)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:986,colon cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:987,Moderate non-heme iron intake in the second quintile (4.98-6.24 mg/day)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:988,Furocoumarins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:989,photosensitizing effect on the skin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:990,ultraviolet radiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:991,melanoma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:992,Dietary furocoumarin intake at higher levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:993,risk factor for cutaneous melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:994,Tobacco
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:995,oral cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:996,MPOWER measure scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:997,Global Health Observatory of World Health Organization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:998,Age-standardized Rates of lip and oral cavity cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:999,Global Burden of Diseases 2021 results tool
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1000,Paraguay
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1001,"MPOWER scores over time than Argentina, Brazil and Uruguay"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1002,Venezuela
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1003,Argentina
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1004,lip and oral cavity cancer indicators among males
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1005,Brazil
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1006,Uruguay
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1007,lip and oral cavity cancer incidence for males and females
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1008,MERCOSUR countries with more rigorous MPOWER tobacco control policies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1009,lip and oral cavity cancer burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1010,Cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1011,global morbidity and mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1012,Eastern Mediterranean Region
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1013,sustainable development goal target 3.4
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1014,Sustainable development goal target 3.4
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1015,non-communicable diseases including cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1016,least progress towards achieving sustainable development goal target 3.4
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1017,Nutritional and lifestyle management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1018,cancer care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1019,"context-specific, achievable and individualized"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1020,Multidisciplinary approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1021,"medical, nutritional, psychological and palliative care"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1022,cancer care effectively
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1023,Cancer care and management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1024,"policymakers, healthcare providers and communities"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1025,"Policymakers, healthcare providers and communities"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1026,evidence-based interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1027,cancer awareness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1028,Second-hand smoke exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1029,lung cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1030,nonsmokers in the United States
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1031,Parental second-hand smoke exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1032,lung cancer in children
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1033,Living with smoking spouses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1034,lung cancer in nonsmokers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1035,More and prolonged second-hand smoke exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1036,Workplace second-hand smoke exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1037,lung cancer risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1038,non-smoking children and domestic partners
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1039,bladder cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1040,postoperative complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1041,Urological guidelines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1042,smoking cessation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1043,Patients treated with transurethral resection of the bladder tumour (TURBT)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1044,intensive smoking cessation Gold Standard Programme (GSP)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1045,Relatives
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1046,Clinicians
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1047,Participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1048,Gold Standard Programme (GSP)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1049,relational and communicative factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1050,Patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1051,pragmatic factors for conducting the Gold Standard Programme (GSP)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1052,health systems in several countries
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1053,this study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1054,direct medical cost of colorectal cancer in Antigua and Barbuda
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1055,prevalence-based cost-of-illness methodology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1056,patients diagnosed with colorectal cancer between 2017 and 2021
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1057,data record abstraction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1058,five-year prevalence of colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1059,top-down and bottom-up approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1060,direct medical costs for colorectal cancer care components
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1061,total annual direct medical costs for colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1062,USD 1.14 million
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1063,major cost drivers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1064,treatment and post-treatment side-effects care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1065,treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1066,"USD 613,650.01"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1067,post-treatment side-effects care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1068,"USD 402,234.50"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1069,overall estimated direct medical unit costs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1070,"USD 139,295.58"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1071,main drivers of direct medical unit costs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1072,"surgery, other complications of treatment, and immunotherapy"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1073,surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1074,"USD 43,467.10"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1075,other complications of treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1076,"USD 28,469.21"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1077,"USD 19,200.00"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1078,economic burden of colorectal cancer in Antigua and Barbuda
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1079,estimates of annual direct medical costs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1080,substantial
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1081,delays in receiving treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1082,decreased chances of survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1083,radiotherapy services
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1084,healthcare systems
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1085,patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1086,timely care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1087,study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1088,key time intervals from diagnosis to start of radiotherapy treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1089,data from 800 patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1090,retrospective analysis of patient records
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1091,patient records
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1092,two public radiotherapy centres in Gauteng Province
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1093,two public radiotherapy centres
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1094,Johannesburg and Pretoria
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1095,durations from diagnosis to commencement of radiotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1096,mean duration of the first consultation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1097,8.32 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1098,average time until a Computed Tomography (CT) simulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1099,13.38 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1100,delays in Gauteng radiotherapy pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1101,need for optimisation of referral processes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1102,resource constraints
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1103,need for strategies to improve cancer care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1104,People who undergo lung cancer screening and continue to smoke
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1105,negative clinical outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1106,lowered survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1107,This pilot study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1108,8-week intervention for smoking cessation after lung cancer screening
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1109,intervention group or control group after lung cancer screening
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1110,Intervention group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1111,combination nicotine replacement therapy plus gain-framed text messaging for 8 weeks
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1112,Control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1113,standard cessation counseling after lung cancer screening
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1114,Assessments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1115,8-week and 3-month follow-ups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1116,self-reported 7-day point prevalence abstinence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1117,14.3% of participants in intervention group at Week 8
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1118,abstinent
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1119,0% of participants in control group at Week 8
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1120,4.8% of participants in intervention group at 3-month follow-up
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1121,0% of participants in control group at 3-month follow-up
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1122,Up to 52.4% of intervention group participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1123,provided patches during study period
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1124,Up to 61.9% of intervention group participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1125,provided lozenges during study period
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1126,Study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1127,modest quit rates for lung cancer screening patients receiving gain-framed text messages and nicotine replacement therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1128,patients with cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1129,caregivers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1130,family members
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1131,communication
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1132,"patients with cancer, caregivers, and family members"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1133,communication module
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1134,"patients with cancer, caregivers, and extended family members"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1135,communication strategies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1136,prompt lists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1137,priority lists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1138,methods of telling others
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1139,delegating
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1140,seeking support
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1141,enhancing communication
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1142,adequate family support
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1143,supervised home-based exercise program
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1144,patients recovering from laparoscopic colorectal cancer surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1145,exercise group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1146,two-month structured exercise program
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1147,control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1148,no structured exercise
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1149,intervention group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1150,98%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1151,adverse events
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1152,role function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1153,cognitive function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1154,physical function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1155,Six-Minute Walk Test
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1156,Short Physical Performance Battery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1157,exercise intervention
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1158,quality of life in colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1159,functional recovery in colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1160,fatigue in colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1161,no significant differences
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1162,anxiety between groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1163,depression between groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1164,sleep quality between groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1165,body composition parameters between groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1166,travel distance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1167,cancer stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1168,four articles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1169,travel distance/time and cancer stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1170,six articles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1171,significant associations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1172,sub-Saharan Africa
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1173,"studies from Scotland, Canada, and the United States"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1174,travel distance and cancer stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1175,papers from Japan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1176,travel distance on cancer stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1177,travel distance and advanced cancer stages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1178,longer travel distance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1179,advanced cancer stage in countries with healthcare access challenges
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1180,healthcare accessibility
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1181,early cancer detection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1182,Functional limitations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1183,preventive healthcare service utilization by people with disabilities in Japan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1184,Comprehensive Survey of Living Conditions (CSLC) in 2022
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1185,functional limitations by the Washington Group Short Set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1186,People with disabilities who did not participate in the general health examination and cancer screenings
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1187,functional limitations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1188,Percentage of people with disabilities among the preventive healthcare service non-participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1189,2.40-3.66%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1190,One-third of people with disabilities among the preventive healthcare service non-participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1191,two or more types of functional limitations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1192,Functional limitations in mobility and self-care (basic activities of daily living [BADL])
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1193,common and dominant issues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1194,No obvious difference
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1195,CSLC2022 and CSLC2016 statistics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1196,Reasonable accommodation for people with BADL related to uni- or multifunctional limitations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1197,increased accessibility to preventive healthcare services
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1198,Frequent sleep trouble
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1199,High physical activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1200,Ballroom dancing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1201,physical well-being of cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1202,psychological well-being of cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1203,mental well-being of cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1204,well-being of cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1205,well-being of healthy partners
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1206,Men
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1207,well-being after ballroom dancing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1208,Healthy partners
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1209,cancer patients after ballroom dancing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1210,Teaching methods of ballroom dancing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1211,cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1212,ECOG performance status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1213,progression-free survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1214,D-dimer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1215,albumin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1216,age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1217,overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1218,tumor volume
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1219,extent of resection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1220,radiotherapy dose
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1221,albumin/D-dimer ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1222,prothrombin time
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1223,Bladder cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1224,Immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1225,Proteomic analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1226,differentially regulated immune-related proteins in bladder cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1227,LC-MS/MS analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1228,120 differentially regulated immune-related proteins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1229,Complement cascade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1230,significantly enriched pathway in bladder cancer immune response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1231,"Proteins C4A, CFB, C4B, C8B, CFH, CFI, C5, C4BPA, C3, and C2"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1232,complement system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1233,immune infiltration and immune checkpoint gene associations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1234,"Hub genes CFB, C4B, CFI, and C2"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1235,significant prognostic value for bladder cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1236,Complement system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1237,immune regulation of bladder cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1238,"CFI, C4A, and C4B"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1239,bladder cancer treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1240,survival in bladder cancer immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1241,Kaposi's sarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1242,a rare malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1243,classical type of Kaposi's sarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1244,the most common type of Kaposi's sarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1245,feet
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1246,overall survival in Kaposi's sarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1247,performance score (ECOG PS)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1248,lymph node involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1249,disease stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1250,5-year overall survival rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1251,82.7%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1252,10-year overall survival rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1253,70.8%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1254,breast cancer with low-HER2 expression levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1255,trastuzumab deruxtecan treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1256,HER2-negative breast cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1257,"HER2-null, HER2-ultralow, and HER2-low groups"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1258,22.3% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1259,HER2-null
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1260,23.7% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1261,HER2-ultralow
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1262,54.0% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1263,HER2-low
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1264,two-thirds of all patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1265,T2 tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1266,T4 tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1267,2.4% of tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1268,11.8% of HER2-negative cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1269,triple-negative
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1270,88.2% of HER2-negative cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1271,hormone-positive
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1272,mean tumor diameter in HER2-ultralow group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1273,0.57 cm than in HER2-null group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1274,mean tumor diameter in HER2-low group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1275,0.34 cm than in HER2-null group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1276,HER2-null tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1277,smaller
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1278,HER2-low group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1279,HER2-null group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1280,hormone positivity or negativity distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1281,hormone-positive cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1282,89.2% of all cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1283,triple-negative breast cancer cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1284,10.8% of all cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1285,HER2-ultralow tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1286,HER2-low tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1287,primary central nervous system tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1288,adults
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1289,genetic heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1290,epigenetic heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1291,Glioblastoma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1292,high infiltrating ability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1293,Radiotherapeutic protocols
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1294,Chemotherapeutic protocols
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1295,Surgical protocols
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1296,Treatment of Glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1297,inefficient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1298,Neuroimaging techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1299,conventional diagnostic approaches
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1300,Tissue biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1301,invasive maneuvers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1302,limitations in providing real-time information
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1303,pseudo-progression from real tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1304,Liquid biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1305,biomarkers in body fluids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1306,Biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1307,nucleic acids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1308,tumor-educated platelets
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1309,minimally invasive method
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1310,dynamic method of diagnosis and monitoring
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1311,data on tumor risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1312,data on prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1313,data on recurrence assessment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1314,Low KM grades
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1315,more aggressive tumor features
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1316,poorer prognosis in gastric cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1317,higher prevalence of Borrmann classification types III-IV
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1318,poorly differentiated histology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1319,advanced T stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1320,higher rates of lymphatic invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1321,higher rates of venous invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1322,higher rates of perineural invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1323,higher rates of positive surgical margins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1324,KM score
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1325,"a valuable, cost-effective histological marker for assessing tumor aggressiveness"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1326,risk stratification when applied to routine H&E-stained slides
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1327,Integrating the KM score into pathological assessment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1328,prognostic accuracy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1329,Axillary lymph node metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1330,overall survival in women with breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1331,High PR expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1332,luminal A subgroup
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1333,Luminal A subgroup
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1334,better prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1335,Tumor diameter greater than 2 cm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1336,lymph node positivity in breast cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1337,Presence of lymphovascular invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1338,PR expression level below 80%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1339,Percentage of progesterone receptor expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1340,other molecular biological markers and clinicopathological parameters when predicting axillary metastasis risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1341,Cancer medications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1342,cardiac issues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1343,Chemotherapy drugs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1344,heart
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1345,decrease in heart's capacity to pump blood efficiently
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1346,reduction in left ventricular ejection fraction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1347,Reduction in left ventricular ejection fraction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1348,heart failure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1349,Anthracyclines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1350,harmful effects on the heart
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1351,Alkylating agents
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1352,Targeted therapies for cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1353,Incidence of heart-related issues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1354,type of medication
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1355,dosage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1356,duration of treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1357,pre-existing heart conditions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1358,direct harm to heart muscle cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1359,damage and programmed cell death in heart cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1360,Conventional biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1361,degree of cardiac damage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1362,managing cardiotoxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1363,Genetic profiling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1364,individuals at risk of cardiotoxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1365,cardiotoxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1366,Personalized medicine approaches
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1367,Novel biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1368,Identification of genetic alterations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1369,personalized treatment approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1370,Personalized treatment approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1371,rates of cardiac events
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1372,high oncological efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1373,Oncology drug-induced cardiotoxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1374,preventive strategies and therapeutic interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1375,Preventive strategies and therapeutic interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1376,cardiac and oncological knowledge
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1377,Lymphocyte-to-Monocyte Ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1378,cancer-associated systemic inflammatory response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1379,Preoperative Lymphocyte-to-Monocyte Ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1380,prognosis of recurrent colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1381,Patients with recurrent colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1382,preoperative Lymphocyte-to-Monocyte Ratio data
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1383,24.72
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1384,Patients with Lymphocyte-to-Monocyte Ratio high group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1385,49.0 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1386,Patients with Lymphocyte-to-Monocyte Ratio low group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1387,38.0 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1388,28.39 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1389,21.3 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1390,Higher preoperative Lymphocyte-to-Monocyte Ratio levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1391,recurrence-free survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1392,aggressive and lethal primary brain tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1393,ATRX
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1394,gene level in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1395,protein level in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1396,OLIG2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1397,MGMT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1398,gene expression level in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1399,protein expression level in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1400,IDH2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1401,OLIG2 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1402,patient survival in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1403,MGMT expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1404,ATRX expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1405,IDH2 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1406,chromatin remodeling in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1407,transcriptional reprogramming in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1408,DNA repair in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1409,metabolic adaptation in glioblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1410,Ovarian cancer surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1411,multiple radical resections
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1412,complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1413,BayesNet
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1414,most effective prediction model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1415,Bayesian network model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1416,highest accuracy compared to all other models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1417,CDC Grade ≥ III complications following epithelial ovarian cancer surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1418,True positive rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1419,76%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1420,False positive rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1421,15.6%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1422,Recall rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1423,76.9%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1424,Overall accuracy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1425,82.2%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1426,AUC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1427,0.863
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1428,high degree of accuracy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1429,ROC analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1430,CDC grade ≥ III
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1431,KRAS genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1432,tumor formation in colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1433,predictive biomarkers for resistance to anti-EGFR therapies in metastatic colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1434,KRAS mutations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1435,45% of metastatic colorectal cancer patients in Turkey
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1436,KRAS mutation rate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1437,female patients compared to male patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1438,Codon 12 mutations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1439,Codon 13 mutations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1440,"G12D, G12V, and G13D mutations"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1441,80% of all detected KRAS mutations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1442,G12V mutation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1443,female patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1444,Routine KRAS genotyping
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1445,personalized treatment strategies for metastatic colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1446,candidate selection for anti-EGFR therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1447,Ovarian cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1448,highly lethal gynecological malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1449,cancer-related deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1450,Diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1451,gynecological examination
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1452,transvaginal ultrasonography
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1453,Gynecology Imaging Reporting and Data System (GI-RADS)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1454,adnexal masses preoperatively
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1455,Combination of IV-V GI-RADS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1456,92.2%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1457,87%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1458,95.9%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1459,adnexal mass malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1460,GI-RADS classification system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1461,reliable method for reporting ovarian masses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1462,malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1463,patient triage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1464,clinical decision making
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1465,incretin-based therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1466,diabetes mellitus
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1467,dipeptidyl peptidase-4 (DPP-4) inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1468,glucagon-like peptide-1 (GLP-1) receptor agonists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1469,dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1470,weight reduction
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1471,metabolic regulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1472,thyroid cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1473,pancreatic cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1474,prostate cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1475,Malignant melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1476,cutaneous cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1477,melanocytes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1478,Melanocytes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1479,pigment-producing cells resident in the skin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1480,rapid and uncontrolled growth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1481,propensity for metastasis to vital organs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1482,Early detection of melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1483,optimizing patient outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1484,Diagnosis at an advanced stage of melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1485,limited treatment options
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1486,Diagnostic modalities for melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1487,clinical evaluations by dermatologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1488,radiological imaging techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1489,Radiological imaging techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1490,ultrasonography
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1491,magnetic resonance imaging (MRI)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1492,computed tomography (CT) scans
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1493,excisional biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1494,targeted therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1495,chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1496,radiation therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1497,Quercetin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1498,antiproliferative
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1499,antioxidant
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1500,anticancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1501,apples
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1502,onions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1503,berries
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1504,citrus fruits
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1505,key carcinogenic pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1506,malignant tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1507,melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1508,DESTINY-Breast trial data
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1509,antibody-drug conjugates in invasive breast cancer expressing low levels of HER2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1510,HER2-low breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1511,immunohistochemistry score of 1+ and 2+ without HER2 gene amplification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1512,hormone receptor-positive breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1513,triple-negative breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1514,HER2-null breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1515,albumin levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1516,survival in patients with pancreatic adenocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1517,HALP score
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1518,LCR value
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1519,low HALP scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1520,shorter overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1521,high HALP scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1522,longer overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1523,low LCR scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1524,shorter survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1525,high LCR scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1526,longer survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1527,high albumin levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1528,low albumin levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1529,disease-free survival in patients with pancreatic adenocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1530,overall survival in patients with pancreatic adenocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1531,Patients with pleural mesothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1532,9 months in first-line treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1533,Chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1534,6 months in first-line treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1535,6 months in third-line treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1536,3 months in third-line treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1537,chemotherapy in third-line treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1538,Absence of metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1539,better immunotherapy outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1540,Prior asbestos exposure in an endemic region
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1541,71.7% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1542,epithelioid
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1543,28.3% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1544,distant metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1545,65% of patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1546,asbestos exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1547,13 of 17 patients tested
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1548,≥1%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1549,Escherichia coli Nissle 1917
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1550,microbial vector for delivery of Glypican-1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1551,Glypican-1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1552,tumor-associated antigen
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1553,pancreatic ductal adenocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1554,GPC1-flagellin fusion protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1555,antigen immunogenicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1556,Glypican-1 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1557,tumor cell growth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1558,Oral immunization with EcN GPC1-FL
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1559,robust systemic immune response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1560,IgG
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1561,IL-10
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1562,IL-2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1563,IFN-γ
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1564,Western blot examination of fecal samples
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1565,consistent antigen expression in gastrointestinal tract
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1566,Consistent antigen expression in gastrointestinal tract
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1567,effective bacterial colonization and antigen retention
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1568,This oral vaccination methodology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1569,no detrimental impacts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1570,cancer immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1571,Effective production of Glypican-1 in tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1572,continuous antigen delivery and immune activation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1573,This microbial-based antigen delivery approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1574,scalable and non-invasive substitute for traditional vaccine platforms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1575,minimally invasive treatment approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1576,open approach in treating early-stage cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1577,open approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1578,short-term benefits
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1579,international guidelines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1580,application of minimally invasive surgery for treating early-stage cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1581,studies published between 1992 and 2017
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1582,minimally invasive treatment approach for early-stage cervical cancer compared with open approach
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1583,"unicentric, non-randomized, and relied on a reduced number of patients"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1584,Laparoscopic Approach to Cervical Cancer (LACC) trial
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1585,minimally invasive approach in treating early-stage cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1586,literature published after 2018
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1587,new randomized and prospective clinical studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1588,studies published after 2018
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1589,deficiencies of the LACC trial
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1590,developing new methods to improve minimally invasive surgical technique
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1591,new methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1592,safety of minimally invasive approach in treating early-stage cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1593,included studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1594,results of the LACC trial
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1595,three ongoing randomized clinical trials
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1596,state of minimally invasive surgical approach for early-stage cervical cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1597,Squamoid eccrine ductal carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1598,cutaneous adnexal malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1599,exceedingly rare
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1600,aggressive
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1601,squamous cell carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1602,biphasic differentiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1603,deep infiltration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1604,perineural invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1605,significant morbidity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1606,poor long-term outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1607,80-year-old female patient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1608,progressive numbness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1609,nasal deviation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1610,subcutaneous indurated lesion in left nasofacial region
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1611,early neurological symptoms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1612,immunohistochemical analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1613,ductal differentiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1614,radical resection with intraoperative margin assessment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1615,Mohs micrographic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1616,adjuvant radiotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1617,62 Gy/31 fractions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1618,high-risk features
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1619,perivascular invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1620,local recurrence involving left orbit and nasal bone
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1621,local recurrence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1622,20 months postoperatively
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1623,aggressive nature
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1624,palliative care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1625,COVID-19
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1626,clinical status of patient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1627,patient demise
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1628,early suspicion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1629,Squamoid eccrine ductal carcinoma diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1630,extensive histopathologic assessment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1631,aggressive multimodal treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1632,Squamoid eccrine ductal carcinoma management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1633,multidisciplinary management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1634,elderly and immunocompromised patients with Squamoid eccrine ductal carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1635,long-term surveillance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1636,high recurrence risk and perineural invasion in Squamoid eccrine ductal carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1637,Breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1638,women
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1639,Anticancer therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1640,cardiovascular complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1641,Autonomic nervous system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1642,heart rate variability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1643,Impaired heart rate variability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1644,36.8% of breast cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1645,Hypertension
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1646,reduced heart rate variability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1647,De novo atrial fibrillation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1648,patients with impaired heart rate variability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1649,Heart rate variability parameters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1650,all-cause mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1651,Cancer stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1652,deterioration of heart rate variability in breast cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1653,Optimal management of cardiovascular risk factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1654,autonomic nervous system dysfunction in cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1655,Anastomotic leakage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1656,colorectal surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1657,morbidity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1658,mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1659,healthcare costs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1660,Aortic calcification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1661,systemic atherosclerosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1662,tissue perfusion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1663,anastomotic healing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1664,Tumor factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1665,anastomotic leakage risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1666,Patient comorbidities
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1667,Preoperative aortic calcification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1668,anastomotic leakage incidence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1669,5.96% of patients undergoing colorectal surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1670,Anastomotic leakage incidence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1671,>50% aortic calcification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1672,anastomotic leakage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1673,Rectal tumor localization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1674,increased anastomotic leakage risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1675,Cardiovascular disease
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1676,Neoadjuvant therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1677,Severe aortic calcification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1678,anastomotic leakage in colorectal surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1679,CEACAM6
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1680,pancreatic cancer progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1681,siCEACAM6
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1682,miR-29a
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1683,pHLIP technology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1684,acidic tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1685,pHLIP-siCEACAM6
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1686,pHLIP-miR-29a
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1687,cell viability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1688,intravenous injection of pHLIP-siCEACAM6
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1689,intravenous injection of pHLIP-miR-29a
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1690,25.1%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1691,21.2%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1692,small RNAs to pancreatic ductal adenocarcinoma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1693,splenectomy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1694,B-cell function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1695,thymectomy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1696,T-cell function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1697,oral immunosuppression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1698,splenectomy and thymectomy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1699,human PDAC cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1700,liver and pancreas of pigs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1701,immunodeficient pig model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1702,low initial dosage of oral immunosuppression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1703,high initial dosage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1704,patient-derived xenografts of pancreatic cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1705,mass formation at cell line injection site
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1706,reactive cell clusters on pathology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1707,Mammography
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1708,Ultrasonography
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1709,Omics-based biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1710,Metabolomics technology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1711,Plasma-based metabolomics panel data
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1712,Breast cancer individuals from healthy controls
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1713,Plasma metabolites
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1714,LC-TOFMS and GC-TOFMS techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1715,Random Forest algorithm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1716,0.963 ± 0.043
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1717,0.977 ± 0.051
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1718,Light Gradient Boosting Machine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1719,0.983 ± 0.028
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1720,0.989
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1721,SHAP analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1722,Metabolomics biomarkers and explainable AI-based prediction model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1723,Proposed XAI system using interpretable metabolite data
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1724,Psoriasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1725,chronic inflammatory skin disease
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1726,Biologic therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1727,key cytokine pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1728,psoriatic lesions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1729,Angiomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1730,benign vascular proliferations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1731,systemic inflammation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1732,hormonal factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1733,Solar lentigines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1734,UV-induced pigmentary lesions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1735,aging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1736,sun exposure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1737,Angioma prevalence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1738,postmenopausal women
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1739,patients with osteoporosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1740,Psoriatic arthritis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1741,greater angioma burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1742,IL-23 inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1743,increased angioma formation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1744,TNF-α inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1745,Methotrexate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1746,protective effect on angioma formation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1747,UVB therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1748,patients with systemic inflammatory conditions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1749,lower solar lentigines lesion counts
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1750,Moderate alcohol consumption
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1751,angiogenesis in psoriasis patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1752,pigmentary changes in psoriasis patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1753,Systemic inflammation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1754,vascular activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1755,melanocytic activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1756,increased prevalence of solar lentigines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1757,NSAIDs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1758,protective effect on solar lentigines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1759,Robotic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1760,longer operative time
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1761,lower rate of conversion to open surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1762,higher lymph node yield
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1763,lower rate of positive circumferential resection margin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1764,lower rate of reoperation within 30 days postoperatively
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1765,estimated blood loss compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1766,postoperative hospital stay compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1767,rates of overall postoperative complications compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1768,rates of severe postoperative complications compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1769,time to first autonomous urination compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1770,time to first flatus compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1771,rate of readmission within 30 days postoperatively compared with laparoscopic surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1772,conversion rates for mid-low rectal cancer surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1773,pathological outcomes for mid-low rectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1774,mid-low rectal cancer surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1775,Obesity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1776,reproductive hormones in Chinese patients with polycystic ovarian syndrome
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1777,Obese PCOS patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1778,luteinizing hormone (LH)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1779,LH/FSH ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1780,progesterone (P)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1781,anti-mullerian hormone (AMH)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1782,testosterone (T)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1783,No significant difference
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1784,follicle-stimulating hormone (FSH) between obese and nonobese PCOS patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1785,estradiol (E2) between obese and nonobese PCOS patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1786,prolactin (PRL) between obese and nonobese PCOS patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1787,patients with incurable cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1788,quality end-of-life care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1789,clinical trials
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1790,advancing cancer care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1791,trial enrollment in the last year of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1792,end-of-life quality metrics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1793,patients enrolled in clinical trials in the last year of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1794,new anticancer treatments in the last 30 days of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1795,palliative care referral
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1796,goals of care documentation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1797,emergency department encounter in the last 30 days of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1798,acute care setting
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1799,enrollment in clinical trials in the last year of life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1800,metrics of aggressive end-of-life care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1801,low rates of palliative care and hospice engagement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1802,opportunities for improvement for all patients regardless of trial enrollment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1803,Integrin glycosylation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1804,invasion and metastasis of malignant tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1805,head and neck squamous cell carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1806,"Integrins ITGA2, ITGA3, ITGA5, ITGA6, ITGB1, and ITGB4"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1807,HNSCC tumor and serum samples
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1808,High intratumoral ITGB1-WFL results
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1809,high T class
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1810,Integrin glycovariant assays
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1811,nodal metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1812,Serum ITGA2-UEA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1813,radiotherapy response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1814,cancer recurrence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1815,Integrin glycovariants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1816,HNSCC tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1817,ITGB1-WFL
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1818,invasiveness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1819,metastatic behavior
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1820,radioresponse
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1821,mortality from liver disease
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1822,People with type 2 diabetes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1823,mortality from hepatic causes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1824,Diabetic individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1825,threefold higher risk of liver-related mortality compared to non-diabetic individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1826,Hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1827,people with diabetes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1828,Metabolic dysfunction-associated steatotic liver disease
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1829,Male gender
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1830,increased hepatic mortality in diabetic individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1831,Advanced age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1832,High FIB-4 scores
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1833,liver fibrosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1834,Poor glycemic control (HbA1c > 9%)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1835,History of alcohol abuse
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1836,Antidiabetic treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1837,reduced liver mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1838,Newer therapies like GLP-1 RAs and SGLT2 inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1839,Insulin treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1840,higher liver mortality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1841,Chordoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1842,primary malignant bone tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1843,lncRNA NEAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1844,Silencing lncRNA NEAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1845,survival of chordoma cell lines MUG-Chor1 and U-CH1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1846,proliferation of chordoma cell lines MUG-Chor1 and U-CH1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1847,apoptosis in chordoma cell lines MUG-Chor1 and U-CH1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1848,Overexpression of iASPP
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1849,effects of silencing lncRNA NEAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1850,cell growth in si-lncRNA NEAT1 group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1851,apoptosis in si-lncRNA NEAT1 group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1852,cell proliferation and division in chordoma tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1853,apoptosis in chordoma tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1854,effects of silencing lncRNA NEAT1 in chordoma tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1855,expression of iASPP
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1856,lncRNA NEAT1/iASPP pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1857,chordoma development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1858,Celastrol
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1859,hepatocellular carcinoma progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1860,FANCD2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1861,hepatocellular carcinoma proliferation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1862,hepatocellular carcinoma invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1863,ferroptosis inhibitor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1864,High expression of FANCD2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1865,poor survival in hepatocellular carcinoma patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1866,SNU-423 and SNU-387 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1867,FANCD2 overexpression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1868,SNU-423 cell viability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1869,SNU-423 cell migration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1870,SNU-423 cell invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1871,SNU-423 tube formation ability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1872,autophagy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1873,FANCD2 knockdown in SNU-387 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1874,"cell viability, migration, invasion, and tube formation ability"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1875,Celastrol-induced autophagy and ferroptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1876,Celastrol inhibition of SNU-423 cell survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1877,FANCD2 knockdown
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1878,Celastrol effects in SNU-387 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1879,autophagy-dependent ferroptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1880,malignant behavior in hepatocellular carcinoma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1881,Protocatechuic acid
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1882,pyroptosis in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1883,viability of glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1884,invasion of glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1885,migration of glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1886,NLRP3 protein and mRNA in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1887,caspase-1 protein and mRNA in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1888,GSDMD protein and mRNA in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1889,NLRP3-specific inhibitor MCC950
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1890,Protocatechuic acid on glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1891,number of invading glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1892,GSDMD positivity in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1893,NLRP3/caspase-1/GSDMD signaling pathway in glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1894,TIM-3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1895,advanced stages with reduced survival in several types of cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1896,dysfunction in T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1897,designing advanced therapy for cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1898,resistance to immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1899,T cell exhaustion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1900,small molecule inhibitors targeting TIM-3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1901,life span
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1902,resistance in therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1903,TIM-3 pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1904,immune response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1905,killer T lymphocytes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1906,natural killer cells (NK cells)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1907,Advanced colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1908,Treatment of advanced colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1909,chemotherapy combined with targeted therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1910,Immunotherapy based on immune checkpoint inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1911,mismatch repair-deficient tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1912,microsatellite instability-high tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1913,Mismatch repair-deficient tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1914,less than 10% of advanced colorectal cancer cases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1915,Microsatellite instability-high tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1916,Chimeric antigen receptor-T cell therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1917,adoptive cell therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1918,modified T-lymphocytes engineered to express chimeric antigen receptors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1919,recognition of surface antigens expressed by tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1920,Hematological malignancies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1921,lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1922,myeloma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1923,leukemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1924,Efficacy of chimeric antigen receptor-T cell therapy in solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1925,limited
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1926,Limitations of chimeric antigen receptor-T cell therapy in solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1927,antigen heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1928,restricted CAR-T cell trafficking into the tumor area
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1929,presence of an immunosuppressive tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1930,Novel chimeric antigen receptor-T cell therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1931,an unmet need for solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1932,Immune checkpoint blockade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1933,various chimeric antigen receptor-T cell models targeting tumor-associated antigens in colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1934,Clinical efficacy of chimeric antigen receptor-T cell therapy for colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1935,limited in early-phase clinical trials
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1936,Factors affecting clinical efficacy of chimeric antigen receptor-T cell therapy for colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1937,trial design
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1938,tumor characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1939,Tumor characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1940,immunosuppressive microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1941,Development of innovative chimeric antigen receptor-T cell models and identification of novel antigens
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1942,effectiveness of chimeric antigen receptor-T cell therapy for colorectal cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1943,Double minutes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1944,extrachromosomal circular chromosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1945,amplified oncogenes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1946,drug resistance genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1947,drug resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1948,Double minutes enhancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1949,target genes in gastric cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1950,tumor immunity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1951,Disruptions in enhancer-transcription factor-target gene regulatory loops
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1952,Target genes regulated by double minutes enhancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1953,immune-related genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1954,increased drug resistance to common chemotherapy agents in gastric cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1955,High expression of drug resistance-related target genes in gastric cancer samples with double minutes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1956,STAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1957,anti-microbial functions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1958,pro-apoptotic functions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1959,loss-of-function mutations in STAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1960,increased susceptibility to infections
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1961,development of tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1962,mice expressing N-terminally truncated STAT1 protein (STAT1-ΔN)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1963,splenomegaly
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1964,splenomegaly in mice expressing STAT1-ΔN
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1965,formation of splenic non-Hodgkin lymphomas
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1966,STAT1-ΔN variant expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1967,disruption of normal spleen architecture
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1968,malignant tumor cells in spleen
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1969,CD3-negative
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1970,CD20-negative
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1971,tyrosine-phosphorylated STAT1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1972,tyrosine-phosphorylated STAT3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1973,tumor cell lysates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1974,cytokine-independent hyperphosphorylation of STAT1 and STAT3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1975,expression level of NF-κB in tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1976,significantly reduced
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1977,DNA-binding activity of STAT1-ΔN
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1978,wild-type STAT1 protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1979,tyrosine-phosphorylated STAT1-ΔN level
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1980,interferon-γ (IFNγ)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1981,lipopolysaccharide (LPS)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1982,combination of IFNγ and LPS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1983,STAT1-ΔN truncation mutant
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1984,nucleus upon cytokine stimulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1985,tumor tissue and isolated lymphoma cells treated with IFNγ/LPS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1986,significantly reduced STAT1-regulated target gene expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1987,lack of STAT1 nuclear accumulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1988,elevated tyrosine-phosphorylation of STAT3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1989,STAT3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1990,oncogene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1991,formation of phospho-STAT3-expressing CD3-negative CD20-negative non-Hodgkin lymphomas in spleen
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1992,Laser en bloc resection of bladder tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1993,Transurethral resection of bladder tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1994,Complete resection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1995,Intact specimen for accurate histologic assessment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1996,Avoiding fragmentation and tumor seeding
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1997,Preventing obturator nerve reflex
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1998,Reduction of inflammatory response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:1999,Holmium laser
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2000,Laser used in en bloc resection of bladder tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2001,Green-light laser
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2002,Thulium laser
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2003,Diode laser
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2004,Exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2005,key carriers of signaling molecules
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2006,Tumor-associated macrophages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2007,natural lipid bilayer structures
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2008,biological activity related to their original cell
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2009,efficient carriers in cancer therapy studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2010,Tumor-associated macrophage-derived exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2011,resistance to cancer therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2012,Macrophage-derived exosomes generated in vitro
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2013,favorable potential in cancer therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2014,cancer metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2015,resistance to cancer therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2016,Modified macrophage-derived exosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2017,unique advantages by their macrophage origin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2018,diverse cancer therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2019,malignant solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2020,35 patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2021,Yantai Yuhuangding Hospital
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2022,January 2018 and March 2023
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2023,22 males
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2024,13 females
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2025,median age of patients with lymphoma and solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2026,62 years
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2027,lymphoma subtypes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2028,diffuse large B-cell lymphoma (DLBCL)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2029,small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2030,marginal zone lymphoma (MZL)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2031,peripheral T-cell lymphoma (PTCL)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2032,follicular lymphoma (FL)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2033,Waldenström macroglobulinemia (WM)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2034,papillary thyroid carcinoma (PTC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2035,colorectal cancer (CRC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2036,lung cancer (LC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2037,gastric cancer (GC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2038,prostate cancer (PCa)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2039,breast cancer (BC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2040,clear cell renal cell carcinoma (ccRCC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2041,pharyngeal squamous cell carcinoma (PSCC)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2042,bladder cancer (BLCA)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2043,lymphoma with solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2044,rare
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2045,elderly males
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2046,Non-Hodgkin's lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2047,most common subtype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2048,most frequent solid tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2049,Gastric cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2050,prevalent digestive system tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2051,cancer deaths
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2052,pronounced heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2053,dynamically evolving tumor microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2054,GC organoids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2055,organoid culture technology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2056,genetic characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2057,phenotypic characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2058,behavioral characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2059,treatment responses in individual patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2060,organoids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2061,immune evasion in gastric cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2062,intratumoral microbiota in gastric cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2063,clinical drug therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2064,novel drug screening
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2065,GC organoid models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2066,limitations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2067,technological advancements
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2068,basic and translational oncological research
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2069,Cancer risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2070,Inflammatory proteins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2071,Genus Collinsella
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2072,Lung cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2073,T-cell surface glycoprotein CD5
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2074,Genus Collinsella on Lung cancer risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2075,Genus Ruminococcaceae UCG005
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2076,Mesothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2077,CCL4
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2078,Genus Ruminococcaceae UCG005 on Mesothelioma risk
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2079,MRI-based fusion model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2080,perineural invasion status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2081,intrahepatic cholangiocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2082,PNI-positive and PNI-negative groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2083,radiomics model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2084,machine learning algorithms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2085,deep learning model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2086,pre-trained ResNet101
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2087,fusion model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2088,"deep learning, radiomics, and clinical features"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2089,logistic regression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2090,strong discrimination for PNI status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2091,0.905 in training set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2092,0.823 in training set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2093,0.760 in external test set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2094,0.778 in external test set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2095,preoperative identification of PNI status in patients with ICC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2096,clinical decision-making regarding preoperative staging and adjuvant therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2097,venetoclax with hypomethylating agents
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2098,elderly patients with acute myeloid leukemia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2099,acute myeloid leukemia patients unfit for standard treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2100,0.57
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2101,0.52
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2102,0.71 in IDH mutation carriers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2103,0.64 in FLT-3 mutation carriers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2104,0.44 in TP53 mutation carriers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2105,neutropenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2106,thrombocytopenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2107,prevalent and lethal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2108,advanced stages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2109,Surgical resection
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2110,limited benefits for advanced HCC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2111,Liver transplantation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2112,Locoregional therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2113,Hepatic arterial infusion chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2114,promising treatment modality for advanced HCC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2115,anti-tumor efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2116,systemic side effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2117,heterogeneous nature
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2118,variable responses to hepatic arterial infusion chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2119,Patient demographics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2120,hepatic arterial infusion chemotherapy success
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2121,Genomic profiles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2122,Advanced imaging techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2123,radiomics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2124,deep learning models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2125,Hepatic arterial infusion chemotherapy combined with immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2126,improved survival outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2127,Hepatic arterial infusion chemotherapy combined with molecular targeted therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2128,Prognostic scoring systems and nomograms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2129,"clinical, molecular, and imaging data"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2130,superior tools for individualized prognostication compared to traditional staging systems
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2131,Understanding predictors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2132,optimizing hepatic arterial infusion chemotherapy efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2133,enhancing survival and quality of life for patients with advanced hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2134,Body mass index (BMI)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2135,Triglyceride (TG) levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2136,High-density lipoprotein-cholesterol (HDL-C) levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2137,Age in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2138,age in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2139,Body mass index (BMI) in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2140,BMI in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2141,Triglyceride (TG) levels in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2142,TG levels in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2143,Low-density lipoprotein-cholesterol (LDL-C) levels in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2144,LDL-C levels in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2145,High-density lipoprotein-cholesterol (HDL-C) levels in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2146,HDL-C levels in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2147,Total cholesterol (TC) levels in breast cancer group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2148,TC levels in control group
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2149,Women aged ≥ 40 years old
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2150,Total cholesterol (TC) levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2151,breast cancer and control groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2152,Low-density lipoprotein-cholesterol (LDL-C) levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2153,H3.3K27M mutation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2154,Diffuse Midline Glioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2155,H3.3K27M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2156,Polycomb Repressive Complex 2 methyltransferase activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2157,global reduction and redistribution of H3K27me3
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2158,CRISPR-Cas9 editing
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2159,"H3.3 wild-type, H3.3K27M, and combinations with EZH2 and EZH1 co-deletion in DMG patient-derived cell lines"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2160,PRC2 loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2161,widespread gene induction including HOX gene clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2162,activation of biological pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2163,K27M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2164,balanced gene deregulation with overall repressive effect on pathway activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2165,Genes uniquely affected by K27M independent of PRC2 loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2166,concordant changes in chromatin accessibility
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2167,Upregulated genes uniquely affected by K27M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2168,more accessible
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2169,Xenografts of H3.3K27M/EZH1/2 WT cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2170,Xenografts of EZH1/2 knockout cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2171,chromatin accessibility
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2172,gene expression independent of H3K27 methylation loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2173,PRC2-independent functions of K27M
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2174,changes in biological pathway activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2175,SCNN1A expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2176,poor prognosis in TNBC patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2177,advanced N stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2178,HER2 status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2179,Ki-67 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2180,histological grade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2181,High SCNN1A expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2182,non-pCR patients compared to pCR patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2183,lower overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2184,lower disease-free survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2185,SCNN1A overexpression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2186,poor prognosis in TNBC patients undergoing neoadjuvant chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2187,non-pCR status in TNBC patients undergoing neoadjuvant chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2188,Polycystic ovary syndrome
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2189,anovulatory infertility
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2190,Cellular senescence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2191,granulosa cells of PCOS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2192,Sphingolipid metabolism disorder
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2193,LYN
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2194,PCOS-related anovulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2195,PLCG2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2196,STAT5B
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2197,MMP9
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2198,IL6R
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2199,"Biomarkers (LYN, PLCG2, STAT5B, MMP9, IL6R)"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2200,immune cell types infiltration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2201,Testosterone-stimulated granulosa cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2202,"biomarkers (LYN, PLCG2, STAT5B, MMP9, IL6R)"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2203,senescence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2204,sphingolipids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2205,Aspirin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2206,senescence in granulosa cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2207,sphingolipid dysregulation in granulosa cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2208,anovulation associated with PCOS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2209,photothermal therapy and metalloimmunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2210,Co + diABZI@J-dICG nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2211,HCC treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2212,Indocyanine green
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2213,J-aggregates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2214,photothermal therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2215,STING agonist diABZI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2216,cGAS-STING pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2217,Cobalt ions (Co2+)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2218,tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2219,HCC recurrence after hepatectomy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2220,machine learning model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2221,distant metastasis in uterine carcinosarcoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2222,peritoneal cytology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2223,Logistic Regression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2224,machine learning algorithm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2225,SVM
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2226,GBM
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2227,Neural Network
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2228,RandomForest
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2229,KNN
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2230,AdaBoost
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2231,LightGBM
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2232,model performance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2233,calibration curves
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2234,DCA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2235,confusion matrices
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2236,sensitivity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2237,specificity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2238,Logistic Regression model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2239,nomogram visualization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2240,SHAP values
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2241,best-performing machine learning model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2242,Peritoneal cytology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2243,distant metastasis in uterine carcinosarcoma patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2244,T stage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2245,tumor size
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2246,prediction models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2247,logistic regression model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2248,0.882 in training set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2249,0.881 in internal test set
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2250,best-performing model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2251,significant potential clinical utility
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2252,DCA curves
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2253,tool
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2254,peritoneal cytology features
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2255,early identification of high-risk patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2256,follow-up and monitoring during tumor development
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2257,optimization of personalized treatment strategies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2258,Non-White populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2259,lower cervical cancer screening rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2260,Older women
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2261,Rural populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2262,Populations with low socioeconomic status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2263,Hispanic individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2264,up-to-date cervical cancer screening
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2265,Non-White individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2266,Foreign-born individuals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2267,Individuals with limited English proficiency
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2268,Older age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2269,Higher comorbidity burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2270,Greater healthcare utilization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2271,Having a female primary care provider
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2272,Inactive online patient portal account
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2273,Individuals with lower socioeconomic status
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2274,Computed Tomography ventilation imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2275,ventilation imaging technique
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2276,CT LVAS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2277,CTVI commercial product
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2278,use in clinical practice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2279,ventilation images
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2280,CTVI_HU
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2281,CTVI_Jac
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2282,CTVI images
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2283,Galligas PET ventilation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2284,Bland-Altman analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2285,overall bias of < 0.01% for all CTVI methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2286,±7.4%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2287,±9.1%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2288,±7.9%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2289,Mean Spearman correlation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2290,0.61 ± 0.14
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2291,0.68 ± 0.10
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2292,0.57 ± 0.15
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2293,Mean DSC for top 85% ventilation function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2294,0.91 ± 0.03 for CT LVAS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2295,0.92 ± 0.02 for CTVI_HU
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2296,0.91 ± 0.03 for CTVI_Jac
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2297,DSC for CTVI_HU
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2298,DSC for CT LVAS and CTVI_Jac
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2299,Mean DSC for top 15% ventilation function
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2300,0.47 ± 0.17 for CT LVAS
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2301,0.53 ± 0.16 for CTVI_HU
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2302,0.47 ± 0.18 for CTVI_Jac
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2303,previous CTVI methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2304,negligible bias for quantification of lobar ventilation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2305,Mean voxel-wise Spearman correlations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2306,moderate to good
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2307,DSC of functionally thresholded lung regions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2308,similar for all CTVI methods
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2309,Triple-negative breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2310,LncRNA RMST
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2311,ITPR1 mRNA for miR-4295 binding
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2312,ITPR1 by miR-4295
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2313,ITPR1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2314,Overexpression of LncRNA RMST
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2315,TNBC cell proliferation and migration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2316,Overexpression of ITPR1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2317,apoptosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2318,miR-4295 overexpression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2319,LncRNA RMST and ITPR1 overexpression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2320,LncRNA RMST-miR-4295-ITPR1 axis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2321,autophagy in TNBC cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2322,systemic immunoinflammatory response index
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2323,C-reactive protein-albumin ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2324,hepatitis B virus-DNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2325,microvascular invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2326,macroscopic vascular invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2327,Edmondson-Steiner grade
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2328,nomogram
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2329,1-year overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2330,3-year overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2331,5-year overall survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2332,different risk groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2333,clinical use
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2334,combination of systemic immunoinflammatory response index and C-reactive protein-albumin ratio
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2335,hepatocellular carcinoma patients undergoing radical surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2336,Chordin-like 1 (CHRDL1)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2337,secreted antagonist of bone morphogenetic proteins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2338,CHRDL1 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2339,tumor tissues compared to normal adjacent tissues in majority of cancer types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2340,Lower CHRDL1 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2341,lung adenocarcinoma (LUAD)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2342,melanoma (SKCM)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2343,mesothelioma (MESO)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2344,CD4⁺ T cells in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2345,CD8⁺ T cells in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2346,B cells in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2347,neutrophils in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2348,macrophages in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2349,dendritic cells in most tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2350,Higher CHRDL1 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2351,more favorable immune profiles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2352,reduction in tumor stemness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2353,CHRDL1 overexpression in A549 and H1299 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2354,"proliferation, migration, and invasion abilities"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2355,CHRDL1 overexpression in A549 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2356,growth in nude mice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2357,CHRDL1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2358,immune checkpoint inhibitor therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2359,early-stage colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2360,advanced colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2361,early-stage colorectal cancer and advanced-stage colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2362,tertiary lymphoid structure
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2363,CD4+ Tfh cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2364,BGC cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2365,CXCL13 expression on CD8+ Tex cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2366,tertiary lymphoid structure functionality
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2367,CD40-CD40L interactions between CD4+ Tfh and BGC cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2368,response to immunotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2369,alterations in tertiary lymphoid structures
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2370,multimodal classification model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2371,single-modal models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2372,physicians in improving breast cancer screening accuracy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2373,mammography and ultrasound images
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2374,six deep learning classification models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2375,Neuroblastoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2376,clinical phenotypes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2377,Computed tomography
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2378,Machine vision imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2379,X-ray imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2380,ultrasound imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2381,YOLOv8-IE
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2382,YOLO algorithm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2383,feature fusion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2384,inverse residual attention mechanisms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2385,YOLO-IE
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2386,Neuroblastoma tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2387,Inverse residual-based attention structure (iRMB)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2388,detection network of YOLOv8
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2389,model's ability to focus on significant image features
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2390,Centered feature pyramid EVC module
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2391,YOLOv8 detection network
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2392,YOLO-IE detection network
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2393,baseline YOLO model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2394,iRMB
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2395,EVC module
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2396,Machine learning and artificial intelligence
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2397,medical diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2398,Weight loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2399,Coffee
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2400,Body weight
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2401,SLC16A6 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2402,Polycystic ovary syndrome patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2403,Obese polycystic ovary syndrome rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2404,Body weight in obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2405,Estrous cycle in obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2406,Ovarian pathology in obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2407,Serum insulin concentration in obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2408,Insulin resistance index in obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2409,SLC16A6 transporter gene expression in ovarian tissue of obese PCOS rats
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2410,PKM2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2411,crucial enzyme that limits the pace of glycometabolism
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2412,most malignancies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2413,bad prognosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2414,PKM2 DNA promoter
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2415,some cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2416,PKM2 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2417,most m6A-methylation-related genes in pan-cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2418,PKM2 functions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2419,regulation of immune system
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2420,hypoxia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2421,epithelial-mesenchymal transition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2422,neutrophils in tumor microenvironment of most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2423,cancer-associated fibroblasts in tumor microenvironment of most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2424,CD274 (PD-L1) in most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2425,CD276 in most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2426,TGF-β1 in most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2427,VEGFA in most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2428,HAVCR2 in most cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2429,Silencing PKM2
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2430,esophageal squamous cell carcinoma to cisplatin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2431,autophagy-regulated tumor cell tolerance to chemotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2432,ALBI-Sarcopenia score
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2433,mortality in hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2434,treatment response in hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2435,Sarcopenia
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2436,43.1% of hepatocellular carcinoma patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2437,Most patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2438,HCV-positive
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2439,CTP A or BCLC B
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2440,TACE
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2441,hepatocellular carcinoma patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2442,Complete response rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2443,from 31.7% at 1 month to 21.4% at 12 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2444,Progressive disease rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2445,from 21.8% at 1 month to 37.8% at 12 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2446,ALBI score
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2447,MELD score
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2448,treatment response at 1 month
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2449,treatment response at 12 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2450,treatment outcomes in hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2451,traditional scoring systems
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2452,patient stratification for optimized treatment planning
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2453,Glioma-associated mesenchymal stem/stromal cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2454,glioma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2455,Hybrid cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2456,lower levels of N6-methyladenosine modification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2457,glioma microenvironment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2458,macrophages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2459,M2-like polarization of macrophages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2460,Fat mass and obesity-associated protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2461,demethylation in hybrids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2462,macrophage colony-stimulating factor secretion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2463,CSF1 RNA stability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2464,m6A-YTH domain family 2-dependent manner
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2465,Oral cavity squamous cell carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2466,most common head and neck region tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2467,Pathologic T4a classification
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2468,"tumor invasion by skin, bone marrow, or depth of invasion > 10 mm and tumor size > 40 mm"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2469,Patients with pT4a gingivobuccal SCC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2470,January 2010 to December 2021
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2471,55%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2472,51.7%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2473,36.7%
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2474,Median follow-up period for all patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2475,93.6 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2476,Median overall survival for patients with shallow DOI (≤ 10 mm)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2477,48.1 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2478,Median overall survival for patients with deep DOI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2479,25.1 months
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2480,Deep DOI tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2481,poorer overall survival in patients classified as pT4a
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2482,Deep DOI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2483,Extranodal extension
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2484,Positive resection margin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2485,bone or skin invasion in patients with pT4a gingivobuccal SCC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2486,body's immune defences
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2487,Suppressing local steroidogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2488,anti-tumour immunity against TNBC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2489,Immunosuppressive steroids
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2490,TNBC patient tumours
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2491,Steroidogenic activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2492,immune-infiltrating regions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2493,Genetic inhibition of immune cell steroidogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2494,TNBC tumour progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2495,tumour associated macrophages
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2496,Steroidogenesis inhibition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2497,anti-tumour immune responses in dendritic and T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2498,glucocorticoid signalling
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2499,Posaconazole
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2500,steroidogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2501,tumour expansion in humanised TNBC mouse model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2502,Incidence of colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2503,different mechanisms driving initiation and progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2504,adenomatous-polyps induced by WNT activation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2505,Colorectal cancer progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2506,p53 loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2507,Early APC loss
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2508,MYC
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2509,URI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2510,MDM2 activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2511,p53 proteasomal degradation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2512,tumour initiation in colorectal cancer mice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2513,mutation burden accrual in colorectal cancer mice
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2514,Reinstating p53 levels via genetic URI depletion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2515,tumour initiation in colorectal cancer mice with WNT pathway activation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2516,p53 super-expression in colorectal cancer mice with WNT pathway activation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2517,tumour initiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2518,lifespan in colorectal cancer mice with WNT pathway activation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2519,lifespan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2520,MYC/URI axis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2521,p53 degradation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2522,transitional mutation acquisition essential for colorectal cancer progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2523,APC loss-driven colorectal cancer initiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2524,two-hit genetic model
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2525,genetic factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2526,Amazonian indigenous populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2527,exome sequencing and bioinformatic tools
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2528,APC gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2529,MLH1 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2530,MSH2 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2531,MSH6 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2532,PMS2 gene
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2533,Three novel variants exclusive to the Amazonian indigenous populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2534,Three high-impact variants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2535,Amazonian indigenous groups
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2536,continental populations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2537,Sacituzumab govitecan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2538,Matrix metalloproteinase 1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2539,many tumor types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2540,tumor metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2541,hormone receptor-positive breast cancer tissues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2542,poorer prognosis among hormone receptor-positive breast cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2543,Hormone receptor-positive breast cancer with high Matrix metalloproteinase 1 expression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2544,NF-κB pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2545,Epithelial-mesenchymal transition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2546,Sacituzumab govitecan resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2547,Temozolomide
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2548,glioblastoma cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2549,TMZ resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2550,TMZ-resistant cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2551,mesenchymal-like state
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2552,mesenchymal-epithelial transition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2553,TLK1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2554,DNA repair protein
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2555,J54
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2556,TLK1 inhibition
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2557,cytotoxicity in TMZ-resistant cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2558,cell migration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2559,cell invasion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2560,primary hepatic malignancy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2561,Cholangiocarcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2562,transplantation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2563,model for end-stage liver disease (MELD) exception points
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2564,Hepatic epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2565,liver transplantation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2566,Fibrolamellar hepatocellular carcinoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2567,metastatic neuroendocrine tumor
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2568,unresectable hepatic colorectal metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2569,Tempus xF+
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2570,liquid biopsy assay
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2571,cell-free DNA in blood samples of patients with advanced solid tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2572,xF+ panel
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2573,523 genes spanning approximately 1.8 Mb of the human genome
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2574,single-nucleotide variants and insertions-deletions in 522 genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2575,copy number gains in 7 genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2576,translocations in 10 genes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2577,blood tumor mutational burden
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2578,Metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2579,Circulating tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2580,primary tumors to bloodstream
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2581,distant organs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2582,unfavorable patient outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2583,Dynamic CTC alterations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2584,cancer regression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2585,biomarkers for diagnoses and prognoses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2586,CTC heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2587,intrinsic oncogenic changes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2588,extrinsic microenvironmental factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2589,Extrinsic microenvironmental factors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2590,circadian rhythm
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2591,genomic/genetic landscapes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2592,epigenomic/epigenetic landscapes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2593,proteomic landscapes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2594,post-translational landscapes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2595,metabolomic landscapes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2596,Intercellular clustering of CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2597,metastatic outcomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2598,CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2599,homotypic multi-cellular clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2600,heterotypic multi-cellular clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2601,CTC clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2602,20-100 times enhanced metastatic potential than single CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2603,cell survival
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2604,stemness
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2605,signaling pathways
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2606,Clustering-driving proteins
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2607,CD44
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2608,CD81
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2609,ICAM1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2610,Podocalyxin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2611,Heterotypic CTC clusters
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2612,CTCs from immune cell attacks
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2613,Cytotoxic immune cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2614,DNA methylation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2615,epigenetic markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2616,control of gene activity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2617,architecture of the nucleus of the cell
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2618,cancer biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2619,liquid biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2620,management of cancer patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2621,circulating genetic material in peripheral blood
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2622,evolution of a solid tumor in real time
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2623,DNA methylation in combination with liquid biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2624,circulating epigenetic biomarkers of clinical importance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2625,DNA methylation markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2626,liquid biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2627,ctDNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2628,gDNA isolated from CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2629,liquid biopsy/DNA methylation analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2630,alterations in DNA methylation in plasma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2631,cancer pathogenesis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2632,methylated DNA
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2633,blood circulating epigenetic biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2634,modified nucleosomes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2635,noncoding RNAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2636,novel biomarkers for improving cancer diagnostics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2637,DNA methylation inhibitors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2638,cancer treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2639,epigenetic alterations detected in CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2640,novel liquid biopsy-based DNA methylation biomarkers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2641,molecular interrogation of patient tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2642,viable and established source of tumor biopsy in prostate cancer with bone metastasis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2643,CTC enumeration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2644,metastatic prostate cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2645,Molecular CTC characterization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2646,effective patient stratification and disease management
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2647,Enrichment technologies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2648,EpCAM-based enrichment to antigen-agnostic enrichment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2649,Clinical utility of CTCs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2650,"enumeration to advanced downstream analyses including CTC proteomics, transcriptomics and genomics"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2651,clinical studies in prostate cancer to determine molecular basis of clinical response and resistance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2652,disease management and treatment customization
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2653,circulating tumor DNA (ctDNA)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2654,circulating tumor cells (CTCs)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2655,cancer diagnosis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2656,cancer monitoring
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2657,traditional tissue biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2658,comprehensive analysis of tumor molecular characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2659,dynamic nature of tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2660,tissue biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2661,tumor heterogeneity over time
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2662,patients with advanced colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2663,diagnosis of colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2664,disease course in colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2665,treatment selection in colorectal cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2666,Identifying genetic changes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2667,personalized medicine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2668,Genetic changes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2669,cancer cells to become resistant to treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2670,Circulating tumor cells (CTCs)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2671,primary tumors into the bloodstream
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2672,cancer heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2673,metastatic disease
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2674,therapy efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2675,invasive tumor biopsies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2676,"genotypic, phenotypic and functional levels"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2677,heterogeneity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2678,leading cause of cancer-related death worldwide
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2679,clinical utility of circulating tumor cells biomarker
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2680,A fraction of circulating tumor cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2681,stem-like feature and partial epithelial-mesenchymal transition phenotype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2682,metastasis initiation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2683,Cancer stem cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2684,primary tumors
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2685,chemotherapy treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2686,immunotherapy treatments
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2687,Hybrid phenotype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2688,epithelial and mesenchymal traits
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2689,cancer stem cell feature
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2690,increased metastatic potential
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2691,Circulating tumor cells subsets
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2692,stem-like and hybrid epithelial-mesenchymal transition phenotype
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2693,Tracking circulating cancer stem cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2694,prognostic and predictive value of circulating tumor cells in non-small cell lung cancer setting
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2695,novel insights into metastatic process
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2696,identification of novel therapeutic targets
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2697,immune-related adverse events
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2698,Giant cell tumour
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2699,parotid gland
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2700,Female patient in her late 40s
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2701,right-sided face swelling in the preauricular region
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2702,Fine-needle aspiration
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2703,primary giant cell tumour of the parotid
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2704,Histopathology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2705,biphasic population of mononuclear stromal cells and osteoclast-like giant cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2706,Cervical lymph node
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2707,metastatic lesion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2708,Tumour
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2709,associated carcinomatous component
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2710,Immunohistochemistry
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2711,haematopoietic markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2712,monocytic-lineage markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2713,mesenchymal markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2714,epithelial markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2715,myoepithelial markers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2716,benign conjunctival fibrous histiocytoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2717,medial rectus
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2718,woman in her 50s
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2719,left eye
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2720,subconjunctival nodule
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2721,nasal conjunctiva
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2722,lesion
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2723,superficial sclera
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2724,insertion of the medial rectus muscle
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2725,histopathological analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2726,benign fibrous histiocytoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2727,Tislelizumab
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2728,anti-programmed cell death protein-1 monoclonal antibody
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2729,standard of care for multiple cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2730,Non-compartmental pharmacokinetic analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2731,Asian and White patients enrolled in BGB-A317-001 and BGB-A317-102
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2732,Population pharmacokinetic analyses
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2733,12 clinical studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2734,intrinsic/extrinsic factors on tislelizumab's pharmacokinetic properties
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2735,race effect on tislelizumab's pharmacokinetic properties
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2736,dose-proportional pharmacokinetics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2737,Tislelizumab pharmacokinetic parameters at 200 mg once every 3 weeks
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2738,BGB-A317-001 (83% White patients) and BGB-A317-102 (100% Chinese patients)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2739,significant covariate for tislelizumab pharmacokinetics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2740,Exposure-efficacy and exposure-safety relationships
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2741,BGB-A317-302 and BGB-A317-303 studies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2742,Incidence of anti-drug antibodies (ADAs)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2743,Asian and White patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2744,Presence of ADAs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2745,tislelizumab's pharmacokinetic properties
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2746,tislelizumab's efficacy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2747,tislelizumab's safety
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2748,Tislelizumab's pharmacokinetic and ADA characteristics
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2749,Asian and White patients with advanced cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2750,in Asian and White patients with advanced cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2751,Immunogenicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2752,tislelizumab's efficacy and safety
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2753,Data from the extensive clinical program of tislelizumab
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2754,tislelizumab across broad patient populations with relevant tumor types
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2755,Tislelizumab 200 mg Q3W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2756,multiple cancers
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2757,Tislelizumab 150 mg Q2W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2758,Tislelizumab 300 mg Q4W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2759,Tislelizumab 400 mg Q6W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2760,Simulated peak serum concentration at 300 mg Q4W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2761,Simulated peak serum concentration at 200 mg Q3W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2762,Simulated peak serum concentration at 400 mg Q6W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2763,Cmax of 5 mg/kg Q3W safety reference
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2764,Trough serum concentration at 400 mg Q6W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2765,Trough serum concentration at 200 mg Q3W
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2766,2 mg/kg efficacy reference Ctrough
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2767,34-year-old male
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2768,8-mm red eroded nodule on left fifth toe
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2769,history of trauma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2770,pyogenic granuloma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2771,shave biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2772,soft white subcutaneous mass
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2773,surrounding dermis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2774,histology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2775,soft-tissue mass with biphasic proliferation of elongated spindle cells with tapered nuclei
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2776,biphasic proliferation of elongated spindle cells with tapered nuclei
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2777,compact cellular foci with palisading (Antoni A)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2778,paucicellular myxoid foci (Antoni B)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2779,schwannoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2780,foot
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2781,dorsum or interdigital space of the foot
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2782,schwannoma of the foot
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2783,podiatrists and dermatologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2784,"schwannoma of the foot when evaluating chronic, non-healing, painful nodules and papules"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2785,Equinus deformity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2786,hemangioma of the calf in children
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2787,Radiotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2788,equinus deformity secondary to hemangioma of the calf
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2789,Electrocoagulation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2790,Surgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2791,Cryosurgery
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2792,Carbon dioxide snow
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2793,Silver nitrate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2794,Sclerosing solutions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2795,Ilizarov external fixator
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2796,equinus deformity caused by an extensive hemangioma in the calf muscles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2797,Techniques using Ilizarov external fixator
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2798,considerable relief with minimal complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2799,"Primary cutaneous diffuse large B-cell lymphoma, leg type"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2800,non-Hodgkin lymphoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2801,fast-growing and aggressive cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2802,bone
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2803,calcaneus
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2804,tarsal bones
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2805,lesser metatarsals
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2806,ankle
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2807,metatarsal bone biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2808,Melanoma invasion of regional lymph nodes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2809,poor prognostic factor for patients with melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2810,Assessing lymph node involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2811,routine part of diagnostic workup for patients with melanoma at T stage ≥T2a
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2812,Histopathological analysis of tissue obtained during sentinel lymph node biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2813,status and degree of melanoma lymph node involvement
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2814,Sentinel lymph node biopsy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2815,technically challenging sample preparation and interpretation by trained pathologist
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2816,Tissue-specific qRT-PCR-based protocol
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2817,melanoma cells within tumor-draining lymph nodes
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2818,Murine models of lymph-node-invasive and lymph-node-noninvasive melanoma cell lines
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2819,qRT-PCR-based protocol
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2820,Melanin-biosynthesis-pathway-specific Trp2 gene expression assay
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2821,highly sensitive strategy for assessing lymph node involvement by melanoma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2822,Therapeutic efficacy improvements
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2823,H9C2 cardiac cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2824,5.5 ± 0.4 µM against MDA-MB-231
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2825,6.25 ± 0.9 µM against MCF7
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2826,20 ± 3.0 µM against HDF cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2827,19.37 ± 2.0 µM against H9C2 cardiac cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2828,promising nanocarrier for Doxorubicin and hydralazine
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2829,Natural products
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2830,non-specific distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2831,precise antitumor effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2832,Fluorescence and singlet oxygen generation of Q-ICG-NLs
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2833,selective near-infrared fluorescence imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2834,perineural invasion of pancreatic cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2835,knockdown of TGFBI
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2836,neural invasion and EMT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2837,PI3K/AKT in Capan-2 and CFPAC-1
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2838,activation of PI3K-AKT pathway
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2839,HR+/HER2- metastatic breast cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2840,Abemaciclib
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2841,Gastrointestinal side effects
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2842,Diarrhoea
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2843,Patients treated with abemaciclib and endocrine therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2844,Above threshold diarrhoea
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2845,≥3 loose/liquid stools daily
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2846,Patients with diarrhoea
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2847,non-prescribed medication
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2848,everyday life
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2849,Symptom monitoring and supportive/educational interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2850,negative impact of diarrhoea on patients' lives
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2851,62% in overall cohort
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2852,in one patient
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2853,RECIST criteria
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2854,treatment response in epithelioid hemangioendothelioma
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2855,Physicians
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2856,decision-making
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2857,Oncologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2858,treatment options
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2859,clinical trial participation
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2860,Clinical trials
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2861,nearly all conversations
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2862,Conversations with Black female patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2863,conversations with white female patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2864,9 of 21 oncologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2865,clinical trial
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2866,decision
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2867,3 of 21 oncologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2868,standard of care
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2869,86% of oncologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2870,43% of oncologists
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2871,inhibition of CDC20/MYBL2 axis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2872,IMPACTOR study
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2873,"abemaciclib treatment for HR+, HER2- metastatic breast cancer"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2874,"HR+, HER2- metastatic breast cancer"
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2875,participants
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2876,side effects from abemaciclib treatment
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2877,family support
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2878,impact of metastatic breast cancer on roles and relationships
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2879,nonroutine discharge in surgical patients with spinal metastases
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2880,implementing a comprehensive nurse-led discharge plan
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2881,SDH-deficient and cumulative succinate
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2882,Younger age
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2883,reporting high distress
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2884,Female sex assigned at birth
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2885,Personal history of cancer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2886,Worry
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2887,commonly patient-reported problem
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2888,Fatigue
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2889,Sleep disturbance
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2890,Distress Thermometer
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2891,patients undergoing cancer genetic counseling experiencing high distress
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2892,higher risk of early post-operative complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2893,higher risk of late morbidities
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2894,higher risk of pre- and post-operative complications
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2895,TP53-induced glycolysis and apoptosis regulator (TIGAR)
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2896,CD44 on cell surface of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2897,immune checkpoint CTLA-4 on cell surface of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2898,immune checkpoint LAG-3 on cell surface of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2899,immune checkpoint PD-1 on cell surface of CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2900,CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2901,Cytokine secretion by CD8+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2902,perforin
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2903,granzyme B
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2904,TNF-α
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2905,CD4+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2906,Cytokine secretion by CD4+ T cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2907,TIGAR suppression in host with 2-DG
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2908,physical therapy interventions
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2909,kinesio taping
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2910,intervention
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2911,compression therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2912,manual lymphatic drainage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2913,exercise
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2914,exercise program plus manual lymphatic drainage supplemented with kinesio taping or compression therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2915,exercise program plus manual lymphatic drainage
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2916,antigen-presenting capacity of dendritic cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2917,an immunosuppressive state
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2918,clinical translation of ferroptosis-based therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2919,Stereotactic body radiation therapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2920,Prescribed dose
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2921,strongest independent predictor of local control
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2922,1-year freedom from local progression rates
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2923,Advanced motion management techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2924,Internal breath-hold with image-guided radiotherapy
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2925,advanced motion management techniques
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2926,high tumor control probability
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2927,Toxicity
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2928,minimal
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2929,Prescribed dose and advanced imaging
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2930,SBRT
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2931,cancer cell death
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2932,Multifunctional platforms
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2933,nanoparticle toxicity and manufacturing issues
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2934,Stimuli-responsive nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2935,Developments in multifunctional platforms and stimuli-responsive nanoparticles
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2936,more individualized and successful OSCC therapies
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2937,promoting tumor progression
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2938,CML patients
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2939,Exosomes of MDA-MB-231 cells
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2940,Size distribution
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2941,Exosome morphology
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2942,Flow cytometry analysis
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2943,cyclin D1 levels
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2944,Tumor mutational burden alone
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2945,immune checkpoint inhibitor response
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2946,Machine learning models
4:54096497-a51b-49c1-979f-bc0dbd8f50d3:2947,immune checkpoint inhibitor treatment decisions
